Novel compounds capable of inducing osteogenic differentiation

A novel compound using PROTAC technology to target MDM2 and induce osteogenic differentiation addresses the need for effective stem cell differentiation into osteoblasts, enhancing bone tissue regeneration.

WO2024237721A1PCT designated stage expired Publication Date: 2024-11-21AJOU UNIV IND ACADEMIC COOP FOUND +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/006699
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2024-05-17
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current methods lack an effective compound capable of inducing osteogenic differentiation of stem cells, which is crucial for bone tissue regeneration and repair.

Method used

A novel compound, specifically designed with an E3 ligand binding module and a linker targeting MDM2, utilizing PROTAC technology to induce osteogenic differentiation by degrading MDM2 and activating p53, thereby promoting stem cell differentiation into osteoblasts.

Benefits of technology

The compound effectively induces osteogenic differentiation of stem cells, as confirmed by biomineralization assays and marker gene expression, demonstrating its potential for bone tissue regeneration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024006699_21112024_PF_FP_ABST
    Figure KR2024006699_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a novel compound capable of inducing osteogenic differentiation of stem cells and, more particularly, to a compound of chemical formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a composition for inducing osteogenic differentiation of stem cells, comprising the compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof. The novel compound based on nutlin, according to the present invention, induces the degradation of MDM2 to efficiently promote the differentiation of mesenchymal stromal cells, and thus, the effect of inducing osteogenic differentiation of stem cells is excellent.
Need to check novelty before this filing date? Find Prior Art

Description

Novel compounds capable of inducing bone differentiation

[0001] The present invention relates to a novel compound capable of inducing osteogenic differentiation of stem cells, and more specifically, to a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a composition for inducing osteogenic differentiation of stem cells comprising the compound, the stereoisomer thereof, or the pharmaceutically acceptable salt thereof.

[0002]

[0003] In the proteasome-mediated protein degradation pathway, proteins are tagged with ubiquitin (Ub) and then degraded in the cytoplasm and nucleus by the proteasome. This ubiquitin-mediated protein degradation regulatory system is responsible for maintaining cellular homeostasis by removing damaged or unnecessary proteins.

[0004] Ubiquitin, a protein composed of 76 amino acids, is involved in a cascade format of E3 (ubiquitin ligase enzyme), and E3, which is composed of a binding domain and a substrate recognition domain, brings the E2-Ub conjugate and the substrate protein (substrate) into close proximity, facilitating the transfer of Ub from E2-Ub to the lysine residue of the substrate protein. Ub can be attached to one or more lysine residues on the substrate protein, or form poly-ubiquitination (poly-Ub) chains that link / multiply mark consecutive Ub molecules with ubiquitin chains. In particular, lysine-48 poly-ubiquitination is delivered to the 26S proteasome, an ATP-dependent protein-degrading enzyme complex, and is unfolded and degraded. This process is called the ubiquitin-proteasome system (UPS). It is known that there are more than 600 types of E3 in these UPSs (Kleiger, G., and Mayor, T. (2014). Perilous Journey: a Tour of the Ubiquitin-Proteasome System. Trends Cel Biol. 24, 352-359.).

[0005] E3s are divided into RING (Really Interesting New Gene)-type E3 ligases, HECT (Homologous to the E6AP Carboxyl Terminus)-type E3 ligases, RBR (RING-Between-RING)-type E3 ligases, and U-box-type E3 ligases depending on the presence of a characteristic domain structure and differences in the mechanism by which Ub is transferred. Among these, U-box-type and RING-type E3 ligases are the most abundant types, and they have a U-box domain and a RING domain, respectively, which serve as anchors for the E2-Ub complex. The U-box domain and RING domain directly bind to E2-Ub to provide proximity between the Ub of the E2-Ub complex and the amino group of the substrate protein, and stimulate catalytic activity through stereoregulation of sites other than the binding site and control the rate of ubiquitination of nearby substrate proteins.

[0006] E3s bind to both E2-Ub and substrate proteins, providing specificity for recognizing substrate proteins to be ubiquitinated. That is, poly-Ublation of substrate proteins is determined by E3 enzymes, and every substrate protein has a recognition site to which a specific E3 binds and a Ub linkage site where ubiquitination occurs. Considering the intracellular environment, which contains approximately 100,000 different proteins, each E3 possesses substrate specificity, but also redundancy and multiplicity.

[0007] The technology that has been studied is PROTAC (Proteolysis-targeting chimera, PROTAC) technology, which induces protein degradation through UPS by poly-Ub-ylating the target protein through these E3s.

[0008] PROTAC is a small molecule that specifically recognizes a target protein and binds to the target protein. When a small molecule that specifically recognizes E3 recognizes and binds to E3, the E3 and the target protein come into close proximity, inducing poly-Ublation of the target protein by E3. The induction of poly-Ublation within the cell ultimately leads to the recognition of the poly-Ub-ylated target protein by the 26S proteasome, an ATP-dependent protein-degrading enzyme complex, resulting in its degradation through the Unified Proteolytic Enzyme System (UPS).

[0009] Under these technical backgrounds, the inventors of the present application have confirmed a novel compound targeting MDM2 based on nutlin, which comprises an E3 ligand as an E3 binding module that specifically recognizes E3; an MDM2 (Mouse double minute 2 homolog) ligand as an E3 as a target protein binding module that specifically recognizes a target protein; and a linker; and its ability to induce osteogenic differentiation of stem cells, thereby completing the present invention.

[0010]

[0011] Summary of the invention

[0012] The purpose of the present invention is to provide a novel compound capable of inducing osteogenic differentiation of stem cells, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0013] The purpose of the present invention is to provide a composition for inducing osteogenic differentiation of stem cells, comprising the compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0014] Another object of the present invention is to provide a method for inducing osteogenic differentiation of stem cells using the compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0015] Another object of the present invention is to provide a use of the compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for inducing osteogenic differentiation of stem cells.

[0016] Another object of the present invention is to provide a method for producing a composition for inducing osteogenic differentiation of stem cells using the compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0017]

[0018] In order to achieve the above object, the present invention provides a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0019]

[0020]

[0021] wherein X is C, O or N, and n is an integer from 1 to 5,

[0022] The above Z is an integer from 1 to 10,

[0023] The above m is an integer between 1 and 10,

[0024] The above YW is C≡C, or both Y and W are C, or the above Y is C and W is O,

[0025] The above v is an integer of any one of 1 to 4,

[0026] The above A is C or N

[0027] The present invention provides a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein l is an integer of any one of 1 to 8.

[0028] The present invention also provides a composition for inducing osteogenic differentiation of stem cells, comprising the compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0029] The present invention also provides a method for inducing osteogenic differentiation of stem cells using the compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0030] The present invention also provides a use of the compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for inducing osteogenic differentiation of stem cells.

[0031] The present invention also provides a use for producing a composition for inducing osteogenic differentiation of stem cells using the compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0032]

[0033] Figures 1a and 1b show the results of confirming the degradation effect of MDM2 by MDM2 targeting PROTAC using RBN ligand. In Figure 1a, 17: tert-butyl 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)acetate,

[0034]

[0035] 18 is as follows:

[0036]

[0037] Figure 2 shows the results of selecting two compounds and treatment concentrations that effectively decompose MDM2 and activate p53.

[0038] Figure 3a shows the results of confirming the biomineralization effect through Alizarin Red S staining for the second selection compound.

[0039] Figure 3b shows the results of confirming the expression of osteogenic differentiation marker genes for the second selection compound.

[0040] Figure 3c shows the results of confirming the biomineralization effect through Alizarin Red S staining targeting compounds 17 to 21.

[0041]

[0042] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Generally, the nomenclature used herein is well known and commonly used in the art.

[0043] In one aspect, a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0044]

[0045]

[0046] wherein X is C, O or N, and n is an integer from 1 to 5,

[0047] The above Z is an integer from 1 to 10,

[0048] The above m is an integer between 1 and 10,

[0049] The above YW is C≡C, or both Y and W are C, or the above Y is C and W is O,

[0050] The above v is an integer of any one of 1 to 4,

[0051] The above A is C or N

[0052] The above relates to a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein l is an integer of any one of 1 to 8.

[0053] "Alkyl" is a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of an aliphatic or alicyclic, saturated or unsaturated (unsaturated, completely unsaturated) hydrocarbon compound. Examples of saturated alkyl include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, etc.; examples of saturated straight-chain alkyl include methyl, ethyl, n-propyl, n-butyl, n-pentyl(amyl), n-hexyl, n-heptyl, etc.; examples of saturated branched-chain alkyl include isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, etc.

[0054] "Alkoxy" means -OR [where R is an alkyl group], examples of which include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, and tert-butoxy.

[0055] "Aryl" means a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound having ring atoms.

[0056] "Alkenyl" is an alkyl group having one or more carbon-carbon double bonds. Examples of unsaturated alkenyl groups include ethenyl (vinyl, -CH=CH2), 1-propenyl (-CH=CHCH3), 2-propenyl, isopropenyl, butenyl, pentenyl, and hexenyl.

[0057] In the present invention, “alkynyl” is an alkyl group having one or more carbon-carbon triple bonds, and examples of unsaturated alkynyl groups include ethynyl and 2-propynyl.

[0058] In the present invention, “formyl” includes -C(=O)H.

[0059] In the present invention, "aryl" refers to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound. For example, " C5-7 "Aryl" means a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, wherein the moiety has 5 to 7 ring atoms, and "C5-10 "Aryl" means a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, wherein the moiety has 5 to 10 ring atoms. Here, the prefix (C 5-7 , C 5-10 etc.) refers to the number or range of ring atoms, regardless of whether they are carbon atoms or heteroatoms. For example, "C 5-6 "Aryl" refers to an aryl group having 5 or 6 ring atoms. Here, the ring atoms may all be carbon atoms, as in a "carboaryl group." Examples of carboaryl groups include, but are not limited to, those derived from benzene, naphthalene, azulene, anthracene, phenanthrene, naphthacene, and pyrene. Examples of aryl groups comprising fused rings, at least one of which is an aromatic ring, include, but are not limited to, groups derived from indane, indene, isoindene, tetralin, acenaphthene, fluorene, phenalene, acephenanthrene, and aceantrene. Alternatively, the ring atoms may include one or more heteroatoms, as in a "heteroaryl group."

[0060] In the present invention, "heteroaryl" is an aryl containing one or more heteroatoms, examples of which include pyridine, pyrimidine, benzothiophene, furyl, dioxalanyl, pyrrolyl, oxazolyl, pyridyl, pyridazinyl, pyrimidinyl, etc., and more specifically, C9 having two fused rings derived from benzofuran, isobenzofuran, indole, isoindole, indolizine, indoline, isoindoline, purine (adenine or guanine), benzimidazole, indazole, benzoxazole, benzisoxazole, benzodioxole, benzofuran, benzotriazole, benzothiofuran, benzothiazole, benzothiadiazole, chromene, isochromene, chroman, isochroman, benzodioxane, quinoline, isoquinoline, quinolizine, benzoxazine, benzodiazine, C having two fused rings derived from pyridopyridine, quinoxaline, quinazoline, cinnoline, phthalazine, naphthyridine, and pteridine 10, C having two fused rings derived from benzodiazepine 11 , C having three fused rings derived from carbazole, dibenzofuran, dibenzothiophene, carboline, perimidine, and pyridoindole 13 , acridine, xanthene, thioxanthene, oxanthrene, phenoxathiine, phenazine, phenoxazine, phenothiazine, thianthrene, phenanthridine, phenanthroline, C having three fused rings derived from phenazine 14 can be heard.

[0061] "Heterocyclyl" refers to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound.

[0062] In the present invention, a prefix (e.g. C) 1-12 , C 3-8 etc.) refers to the number or range of ring atoms, regardless of whether they are carbon atoms or heteroatoms. For example, the term "C" as used herein 3-6 "Heterocyclyl" refers to a heterocyclyl group having 3 to 6 ring atoms.

[0063] Examples of monocyclic heterocyclyl groups include, but are not limited to, those derived from:

[0064] N1: Aziridine, azetidine, pyrrolidine, pyrroline, 2H- or 3H-pyrrole, piperidine, dihydropyridine, tetrahydropyridine, azepine;

[0065] N2: Imidazolidine, pyrazolidine, imidazoline, pyrazoline, piperazine;

[0066] O1: Oxirane, oxetane, oxolane, oxol, oxane, dihydropyran, pyran, oxepin;

[0067] O2: Dioxolane, dioxane and dioxepane;

[0068] O3: Trioxane;

[0069] N1O1: Tetrahydrooxazole, Dihydrooxazole, Tetrahydroisoxazole, Dihydroisoxazole, Morpholine, Tetrahydrooxazine, Dihydrooxazine, Oxazine

[0070] S1: Tiran, Tietan, Tiolan, Tian, ​​Tiefan;

[0071] N1S1: Thiazolines, thiazolidines, thiomorpholines;

[0072] N2O1: Oxadiazine;

[0073] O1S1: oxathiol, oxathiane; and

[0074] N1O1S1: Oxathiazine.

[0075]

[0076] Specifically, it can be a compound where X is C and n is 1, a compound where X is C and n is 2, a compound where X is C and n is 3, a compound where X is O and n is 1, a compound where X is O and n is 2, or a compound where X is O and n is 3.

[0077] In a specific embodiment according to the present invention, it may be one or more of compounds selected from the group consisting of:

[0078] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5 dihydro-1H-imidazole-1-carbonyl) -2-oxopiperazin-1-yl)-N-(5-((2-(2,6dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl) acetamide;

[0079] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(8-((2-(2,6-dioxo-opiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl) acetamide;

[0080] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(11-((2-(2,6-dioxop-erydin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy) undecyl) acetamide;

[0081] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) ) oxy) ethoxy) ethyl) acetamide;

[0082] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(2-(2-((2-(2,6-dioxo-opiperidin-3-yl))-1,3-dioxoisoindoline-) 4-yl)oxy)ethoxy)ethoxy)ethoyl)acetamide;

[0083] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl))-1,3-dioxo) isoindolin-4-yl)oxy))ethoxy)ethoxy)-ethoxy)ethyl)-acetamide.

[0084] The specific synthetic process and conditions of the compound are as follows:

[0085]

[0086] Preparation and conditions: (i) H2, Pd / C, (Boc)2O, THF, rt, 1 h; (ii) DIPEA, CH3CN, 70°C, 16 h; (iii) TFA, CH2Cl2, rt, 1 h; (iv) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0087]

[0088]

[0089] In a specific embodiment according to the present invention, it may be one or more of compounds selected from the group consisting of:

[0090] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl))oxy)acetamide)ethyl)-acetamide;

[0091] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(5-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)) oxy) acetamide) pentyl-l) acetamide;

[0092] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(8-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl))oxy)acetamide)octyl)-acetamide.

[0093] The specific synthetic process and conditions of the compound are as follows:

[0094]

[0095] Preparation and conditions: (i) HATU, DIPEA, DMF, rt, 16 h; (ii) TFA, CH2Cl2, rt, 1 h; (iii) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0096]

[0097] In a specific embodiment according to the present invention, it may be one or more of compounds selected from the group consisting of:

[0098] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(6-(2-(2,6-dioxopipe-lysin-3-yl)-1,3-dioxoisoindolin-4-yl)hexa-5-yn-1-yl) acetamide;

[0099] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)non-8-yn-1-yl) acetamide; and

[0100] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(12-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) dodeca-11-yn-1-yl) acetamide.

[0101] The specific synthetic process and conditions of the compound are as follows:

[0102]

[0103] Formulations and conditions: (i) (COCl)2, DMSO, DIPEA, CH2Cl2, -78 ºC to -30°C, 1 h or PCC, Al2O3, CH2Cl2, rt, 3 h; (ii) Dimethyl (1-diazo-2-oxopropyl)phosphonate, K2CO3, CH3OH, rt, 12 h, (iii) CuI, PdCl2(PPh3)2, Et3N, DMF, 80℃, 16 h; (iv) TFA, CH2Cl2, rt, 1 h; (v) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0104]

[0105] In a specific embodiment according to the present invention, the compound may be:

[0106] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)acetamide.

[0107] The specific synthetic process and conditions of the compound are as follows:

[0108]

[0109] Preparation and conditions: (i) DIPEA, NMP, 90°C, 17 h; (ii) TFA, CH2Cl2, rt, 1 h; (iii) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0110] In a specific embodiment according to the present invention, the compound may be:

[0111] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)phenyl) but-3-yn-1-yl)acetamide.

[0112] The specific synthetic process and conditions of the compound are as follows:

[0113]

[0114] Preparation and conditions: (i) CuI, PdCl2(PPh3)2, Et3N, DMF, 80°C, 3 h; (ii) MsCl, NEt3, CH2Cl2, 0°C->rt, 25 h; (iii) K2CO3, DMF, 60°C, 4 h; (iv) TFA, CH2Cl2, rt, 1 h; (v) nutlinic acid, HATU, DIPEA, DMF, rt, 16 h.

[0115] In a specific embodiment according to the present invention, the compound may be:

[0116] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)phenyl) butyl)acetamide.

[0117] The specific synthetic process and conditions of the compound are as follows:

[0118]

[0119] Formulations and conditions: (i) H2, Pd / C, ethyl acetate, rt, 2 h; (ii) MsCl, NEt3, CH2Cl2, 0℃->rt, 20 h; (iii) K2CO3, DMF, 60°C, 4 h; (iv) TFA, CH2Cl2, rt, 1 h; (v) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0120] In a specific embodiment according to the present invention, the compound may be:

[0121] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)nonyl)acetamide.

[0122] The specific synthetic process and conditions of the compound are as follows:

[0123]

[0124] Formulations and conditions: (i) (Boc)2O, CH2Cl2, 0℃->rt, 3 h; (ii) PCC, Al2O3, CH2Cl2, rt, 3 h; (iii) Dimethyl (1-diazo-2-oxopropyl)phosphonate, K2CO3, CH3OH, rt, 4 h; (iv) CuI, PdCl2(PPh3)2, Et3N, DMF, 80°C; (v) H2, Pd / C, ethanol, rt, 63 h; (vi) TFA, CH2Cl2, rt, 1 h; (vii) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0125] In a specific embodiment according to the present invention, the compound may be:

[0126] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(2-((4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)benzyl )oxy)ethyl)acetamide.

[0127] The specific synthetic process and conditions of the compound are as follows:

[0128]

[0129] Formulations and conditions: (i) imidazole, TBSCl, THF, 0℃->rt, 12 h; (ii) PPh3, imidazole, I2, Et2O / MeCN (3:1), rt, 1h; (iii) TBAI, KOH, THF, rt, 40 h; (iv) TBAF, THF, rt, 3 h; (v) MsCl, DIPEA, DCM, 0℃->rt, 16 h; (vi) NaHCO3, KI, DMF, 80°C, 16 h; (vii) TFA, CH2Cl2, rt, 1 h; (viii) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0130] Compounds may contain asymmetric centers and thus may include enantiomers and diastereomers. "Enantiomers" refer to two stereoisomers of a compound that are non-superimposable mirror images of each other. When compounds disclosed herein have two or more asymmetric centers, they may also exist as diastereomers. Enantiomers and diastereomers belong to the broader class of stereoisomers. All possible stereoisomers are intended to be included, such as substantially pure isolated enantiomers, racemic mixtures thereof, and mixtures of diastereomers. All stereoisomers of the compounds disclosed herein and / or pharmaceutically acceptable salts thereof are intended to be included. Unless otherwise stated, reference to one isomer applies to the other possible isomers. Whenever an isomer composition is not specified, all possible isomers are included.

[0131] "Substantially pure" means that the target stereoisomer comprises no more than 35% by weight of the other stereoisomer(s), such as no more than 30%, further no more than 25%, or even no more than 20%. In some embodiments, the term "substantially pure" means that the target stereoisomer comprises no more than 10% by weight of the other stereoisomer(s), such as no more than 5%, such as no more than 1%.

[0132] As a “pharmaceutically acceptable salt”, an acid addition salt formed by a pharmaceutically acceptable free acid can be used, and an organic acid or an inorganic acid can be used as the free acid.

[0133] The organic acids include, but are not limited to, citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, metasulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, glutamic acid, and aspartic acid. The inorganic acids also include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid.

[0134] For example, if the compound is an anion or has a functional group that can be an anion (e.g., -COOH can be -COO-), it can form a salt with a suitable cation. Examples of suitable inorganic cations include alkali metal ions, such as Na + and K + , alkaline earth metal cations, such as Ca 2+ and Mg 2+ and other cations, such as Al 3+ Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e., NH4 + ) and substituted ammonium ions (e.g. NH3R + , NH2R2 + , NHR3 + , NR4 +) but is not limited to these.

[0135] Examples of suitable substituted ammonium ions include those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids such as lysine and arginine. An example of a common quaternary ammonium ion is N(CH3). 4+ am.

[0136] If the compound is a cation or has a functional group that can be a cation (e.g., -NH2 is -NH3) + (which may be ), can form salts with suitable anions. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfurous acid, nitric acid, nitrous acid, phosphoric acid, and phosphorous acid.

[0137] Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyoxybenzoic acid, acetic acid, ascorbic acid, aspartic acid, benzoic acid, camphorsulfonic acid, cinnamic acid, citric acid, edetic acid, ethanedisulfonic acid, ethanesulfonic acid, fumaric acid, glutaptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxymaleic acid, hydroxynaphthalene carboxylic acid, isethionic acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, methanesulfonic acid, mucic acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, pantothenic acid, phenylacetic acid, phenylsulfonic acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, Examples include toluenesulfonic acid and valeric acid. Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose, and the like.

[0138] From another aspect, the present invention relates to a composition for inducing osteogenic differentiation of stem cells, comprising the compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0139] The above osteogenic differentiation may be the differentiation of bone cells or stem cells into osteoblasts.

[0140] "Stem cell" means a cell that has self-renewal ability that is pluripotent or totipotent and can differentiate into cells of all tissues of an organism, and includes embryonic stem cells, induced pluripotent stem cells, and adult stem cells.

[0141] "Embryonic stem cells" are derived from a fertilized egg, which is created when a male gamete, a sperm cell, and a female gamete, an egg cell, unite. Embryonic stem cells are obtained from the inner cell mass of a blastocyst stage embryo before implantation, and are undifferentiated cells that have the ability to differentiate into cells of all tissues, but can proliferate indefinitely in an undifferentiated state if given culture conditions. In other words, in a special differentiation culture environment, cell differentiation can be induced in the desired direction, and it is expected that a single embryonic stem cell line can be used to treat numerous patients.

[0142] "Induced pluripotent stem cells" are cells that have been induced to have pluripotent differentiation ability through an artificial process of dedifferentiation of differentiated cells, and are also called induced pluripotent stem cells (iPSC).

[0143] "Adult stem cells" are primitive cells isolated from the tissues of mammals, including humans, that are just before differentiation. They have the ability to proliferate indefinitely and differentiate into various types of cells (e.g., fat cells, cartilage cells, muscle cells, bone cells, etc.).

[0144] "Differentiation" refers to the process by which less specialized cells develop into specialized cells, changing their size, shape, membrane potential, metabolic activity, and response to signals. This differentiation primarily occurs during the process by which multicellular organisms form complex tissues from a single zygote, or in adulthood, when adult stem cells differentiate into specialized cells to repair damaged tissues.

[0145] The composition according to the present invention may be a pharmaceutical composition.

[0146] The pharmaceutical composition according to the present invention may be administered by any route. The composition of the present invention may be administered to an animal by any suitable means, either directly (e.g., topically, by injection, implantation or local administration into a tissue site) or systemically (e.g., parenterally or orally). When the composition of the present invention is administered parenterally, such as intravenously, subcutaneously, ophthalmically, intraperitoneally, intramuscularly, buccally, rectally, intraorbitally, intracerebrally, intracranially, intraspinally, intraventricularly, intrathecally, intracisternally, intracapsularly, intranasally or as an aerosol, the pharmaceutical composition may, for example, comprise a portion of an aqueous or physiologically applicable fluid suspension or solution. Accordingly, a carrier or vehicle that is physiologically acceptable can be added to the composition and delivered to the patient. Accordingly, a carrier such as a body fluid for the formulation can generally include physiological saline solution.

[0147] Additionally, the frequency of administration will vary depending on the pharmacokinetic parameters of the formulation used. Typically, clinicians will administer the pharmaceutical composition until the desired effect is achieved. Accordingly, the pharmaceutical composition may be administered as a single dose, as two or more doses spaced apart, or as a continuous infusion via an implantable device or catheter. Further refinement of the appropriate dosage is routinely performed by those skilled in the art and falls within the scope of their routine practice.

[0148] Additionally, the unit dosage is 0.01 μg / kg to 100 mg / kg in humans, specifically 1 μg / kg to 10 mg / kg of body weight. Although the above amount is the optimal amount, it may vary depending on the disease to be treated and the presence or absence of side effects, and the optimal dosage can be determined using routine experiments. Administration of the fusion protein can be by periodic bolus injections, or by continuous intravenous, subcutaneous, or intraperitoneal administration from an external reservoir (e.g., an intravenous bag) or internal source (e.g., a bioerodable implant).

[0149] Suitable routes include oral, parenteral (including subcutaneous, intramuscular, intravenous, intraarterial, inhalational, intradermal, intrathecal, epidural, and infusion techniques), transdermal, rectal, intranasal, topical (including buccal and sublingual), vaginal, intraperitoneal, intrapulmonary, and intranasal administration. Topical administration may include the use of transdermal delivery devices, such as transdermal patches or iontophoresis devices.

[0150] The preferred route may vary, depending on, for example, the condition of the recipient. For oral administration, the composition may be formulated as a pill, capsule, tablet, etc., with a pharmaceutically acceptable carrier, lubricant, or excipient. For parenteral administration, the composition may be formulated as a unit-dose injection with a pharmaceutically acceptable parenteral vehicle or diluent.

[0151] The pharmaceutical composition may further comprise a pharmaceutically acceptable carrier, which is commonly used in the formulation of drugs, and may be at least one selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like, but is not limited thereto. The pharmaceutical composition may further comprise at least one selected from the group consisting of diluents, excipients, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, and preservatives, which are commonly used in the preparation of pharmaceutical compositions.

[0152] The effective amount of the pharmaceutical composition may be administered orally or parenterally. Parenteral administration may include intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intrapulmonary administration, and rectal administration. Since proteins or peptides are digested when administered orally, oral compositions may be formulated to coat the active agent or protect it from stomach degradation. Furthermore, the composition may be administered via any device capable of transporting the active agent to target cells.

[0153] "Treatment" refers to any sign of success in the treatment or amelioration of an impairment, pathology, or condition, including any subjective or objective parameter, such as alleviation; remission; making symptoms or impairments more tolerable to the patient; reducing the pathology or condition; slowing the rate of regression or decline; creating a less debilitating final point of regression; or improving the physical or mental well-being of the patient. Treatment or amelioration of symptoms may be based on objective or subjective parameters, including physical examination, neuropsychiatric testing, and / or psychiatric evaluation.

[0154] An "effective amount" is generally an amount sufficient to reduce the severity or frequency of a symptom, eliminate a symptom, or prevent the onset of a symptom or its underlying cause, or ameliorate or correct impairment resulting from or associated with a disease condition.

[0155] An effective amount is a therapeutically effective amount or a prophylactically effective amount. A "therapeutically effective amount" is an amount sufficient to correct a disease state or symptom, particularly a condition or symptom associated with a disease state, or otherwise prevent, impede, delay, or reverse the progression of a disease state or any other undesirable symptom associated with the disease in any way. A "prophylactically effective amount" is an amount of a pharmaceutical composition that, when administered to a subject, has the intended prophylactic effect, e.g., preventing or delaying the onset of a disease state, or reducing the likelihood of onset (or recurrence) of a disease state or associated symptom.

[0156] Example

[0157] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.

[0158] Manufacturing Example 1. Materials and Methods

[0159] Unless otherwise stated, reagents were obtained from suppliers and used without further purification. Anhydrous THF, DMF, DCM, ACN, and DMSO were purchased from Sigma-Aldrich. Pyridinium chlorochromate (PCC), 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluophosphate (HATU), dimethyl (1-diazo-2-oxopropyl)phosphonate, copper(I) iodide (CuI), and bis(triphenylphosphine)palladium(II) dichloride (PdCl2(PPh3)2), (Boc)2O (Di-tert-butyl dicarbonate), DIPEA (N,N-Diisopropylethylamine), and TFA (trifluoroacetic acid) were purchased from Sigma-Aldrich, Acros Organics, Alfa Aesar, Angele, Combi-blocks or TCI were purchased and used as received unless otherwise stated. Reactions were performed under N2 atmosphere using anhydrous solvents unless otherwise stated. Reaction temperature was controlled by an IKAmag thermostat unless otherwise stated. Analytical thin layer chromatography (TLC) was performed using TLC silica gel 60 F254 (Merck) and visualized by UV fluorescence quenching, ninhydrin, and KMnO4 staining. Flash column chromatography was performed on a Biotage® Selekt Flash Purification System using Biotage® Sfar Silica and Biotage® Sfar C18 D-Duo 100Å cartridges. Preparative HPLC was performed on an Agilent 1260 system with an Agilent 10 prepC18 column (100Å, length 250 mm, i.d. 21.2 mm, 10 μm) at a solvent flow rate of 20 mL / min.All NMR spectra were recorded on a Bruker JNM-ECZR 600 MHz spectrometer. 1 H NMR spectra were reported relative to residual CDCl3 (δ 7.26 ppm), CD3OD (3.31 ppm) or (CD3)2SO (δ 2.50 ppm). 13 The C NMR spectrum was reported relative to residual CD3OD (δ 49.00 ppm). 1 H, 13 C data are reported in chemical shift (δ ppm). IR spectra were recorded by a Nicolet iS50 FT-IR spectrometer using the ATR method and expressed in wavenumber (cm -1 ) was reported. HRMS was obtained with a Bruker Ultra High-Resolution ESI Q-TOF mass spectrometer.

[0160] Manufacturing Example 2. Method

[0161] Manufacturing Example 2-1. Synthesis of 6a-f:

[0162]

[0163] Preparation and conditions: (i) H2, Pd / C, (Boc)2O, THF, rt, 1 h; (ii) DIPEA, CH3CN, 70°C, 16 h; (iii) TFA, CH2Cl2, rt, 1 h; (iv) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0164] A. General method for the synthesis of 3a to f: To a stirred solution of azide (1.00 equiv.) in anhydrous THF was added (Boc)2O (1.20 equiv.). The reaction mixture was purged with nitrogen, and 10% Pd / C (0.10 equiv.) was added. The reaction mixture was stirred at 25°C for 1 h under a hydrogen atmosphere (balloon pressure). After completion of the reaction, the mixture was filtered through Celite and washed with ethyl acetate. The filtrate was concentrated under reduced pressure. The crude material was purified by flash column chromatography on silica gel, eluting with ethyl acetate / hexane, to give the desired product in 68-80% yield.

[0165]

[0166] 5-((tert-Butoxycarbonyl)amino)pentyl 4-methylbenzenesulfonate, 3a: The title compound was synthesized using general method A and obtained as a yellow liquid in 68% yield.

[0167] 1 H NMR (600 MHz, CDCl3) δ 7.80-7.77 (m, 2H), 7.34 (d,J= 8.0 Hz, 2H), 4.49 (bs, 1H), 4.01 (t,J= 6.4 Hz, 2H), 3.10-3.01 (m, 2H), 2.45 (s, 3H), 1.68-1.62 (m, 2H), 1.46-1.39 (m, 11H), 1.36-1.30 (m, 2H).

[0168]

[0169] 8-((tert-butoxycarbonyl)amino)octyl 4-methylbenzenesulfonate, 3b: The title compound was synthesized using general method A and obtained as a colorless viscous liquid in 74% yield.

[0170] 1H NMR (600 MHz, CDCl3) δ 7.80-7.77 (m, 2H), 7.34 (d,J= 8.0 Hz, 2H), 4.49 (bs, 1H), 4.01 (t,J= 6.5 Hz, 2H), 3.08 (q,J= 6.7 Hz, 2H), 2.45 (s, 3H), 1.66-1.56 (m, 4H), 1.44 (s, 9H), 1.33-1.18 (m, 8H).

[0171]

[0172] 11-((tert-butoxycarbonyl)amino)undecyl 4-methylbenzenesulfonate, 3c: The title compound was synthesized using general method A and obtained as a white sticky solid in 80% yield.

[0173] 1 H NMR (600 MHz, CDCl3) δ 7.80-7.77 (m, 2H), 7.34 (d,J= 8.0 Hz, 2H), 4.49 (bs, 1H), 4.01 (t,J= 6.5 Hz, 2H), 3.12-3.04 (m, 2H), 2.45 (s, 3H), 1.67-1.59 (m, 3H), 1.44 (s, 9H), 1.32-1.17 (m, 15H).

[0174]

[0175] 2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethyl 4-methylbenzenesulfonate, 3d: The title compound was synthesized using general method A and obtained as a colorless rubbery liquid in a yield of 70%.

[0176] 1 H NMR (600 MHz, CDCl3) δ 7.82-7.79 (m, 2H), 7.35 (d,J= 8.0 Hz, 2H), 4.80 (bs, 1H), 4.19-4.14 (m, 2H), 3.64-3.61 (m, 2H), 3.45 (t,J= 5.2 Hz, 2H), 3.26-3.20 (m, 2H), 2.45 (s, 3H), 1.45 (s, 9H).

[0177]

[0178] 2,2-Dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl 4-methylbenzenesulfonate 6, 3e: The title compound was synthesized using general method A and obtained as a pale yellow rubbery liquid.

[0179] 1 H NMR (400 MHz, CDCl3) δ 7.80 (d,J= 8.0 Hz, 2H), 7.34 (d,J= 8.0 Hz, 2H), 5.30 (s, 0H), 4.94 (s, 1H), 4.17 (t,J= 4.8 Hz, 2H), 3.69 (t,J= 4.9 Hz, 2H), 3.56 (qd,J= 4.9, 1.9 Hz, 4H), 3.50 (t,J= 5.2 Hz, 2H), 3.29 (q,J= 5.5 Hz, 2H), 2.45 (s, 3H), 1.67-1.56 (m, 0H), 1.43 (s, 9H).

[0180]

[0181] 2,2-Dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl 4-methylbenzenesulfonate, 3f: The title compound was synthesized using general method A and obtained as a colorless rubbery liquid in 77% yield.

[0182] 1 H NMR (600 MHz, CDCl3) δ 7.81-7.78 (m, 2H), 7.34 (d,J= 7.9 Hz, 2H), 5.02 (bs, 1H), 4.18-4.15 (m, 2H), 3.71-3.68 (m, 2H), 3.62-3.57 (m, 8H), 3.52 (t,J= 5.2 Hz, 2H), 3.32-3.26 (m, 2H), 2.44 (s, 3H), 1.43 (s, 9H).

[0183] B. General method for the synthesis of 5a-f: To a stirred solution of tosyl (1.10 equiv) in anhydrous acetonitrile was added potassium 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-oleate (1.00 equiv) and DIPEA (10.00 equiv). The reaction mixture was stirred in a sealed tube at 70°C for 16 h. After the reaction was completed, it was cooled to room temperature, filtered through Celite, and washed with ethyl acetate. The filtrate was removed under reduced pressure, and the crude material was purified by flash column chromatography on silica gel, eluting with acetone / hexane, to give the desired product in 40-85% yield.

[0184]

[0185] tert-Butyl (5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)c-albamate, 5a: The title compound was obtained as an off-white solid in 55% yield using method B.

[0186] 1 H NMR (600 MHz, CDCl3) δ 7.96 (s, 1H), 7.67 (dd,J= 8.4, 7.3 Hz, 1H), 7.46 (d,J= 7.1 Hz, 1H), 7.21 (d,J= 8.4 Hz, 1H), 4.95 (dd, J = 12.6, 5.4 Hz, 1H), 4.62 (s, 1H), 4.22-4.14 (m, 2H), 3.18-3.11 (m, 2H), 2.93-2.87 (m, 1H), 2.85-2.78 (m, 1H), 2.73 (ddd,J= 16.9, 13.6, 5.0 Hz, 1H), 2.16-2.11 (m, 1H), 1.93-1.88 (m, 2H), 1.61-1.52 (m, 4H), 1.44 (s, 9H).

[0187]

[0188] tert-Butyl (8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl)carbamate, 5b: The title compound was obtained as a yellow solid in 50% yield using method B.

[0189] 1 H NMR (600 MHz, CDCl3) δ 8.12 (s, 1H), 7.67 (dd,J= 8.5, 7.3 Hz, 1H), 7.45 (d,J= 7.1 Hz, 1H), 7.21 (d,J= 8.5 Hz, 1H), 4.99-4.92 (m, 1H), 4.54 (s, 1H), 4.21-4.13 (m, 2H), 3.14-3.08 (m, 2H), 2.92-2.87 (m, 1H), 2.86-2.79 (m, 1H), 2.77-2.70 (m, 1H), 2.16-2.09 (m, 1H), 1.87 (p,J= 7.4, 6.9 Hz, 2H), 1.53-1.42 (m, 13H), 1.40-1.29 (m, 6H).

[0190]

[0191] tert-Butyl (11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)undecyl)carbamate 5c: The title compound was obtained as an off-white solid in 40% yield by method B.

[0192] 1H NMR (600 MHz, CDCl3) δ 7.98 (s, 1H), 7.66 (dd,J= 8.5, 7.3 Hz, 1H), 7.44 (d,J= 7.3 Hz, 1H), 7.20 (d,J= 8.5 Hz, 1H), 4.94 (dd,J= 12.5, 5.4 Hz, 1H), 4.49 (bs, 1H), 4.16 (t,J= 6.6 Hz, 2H), 3.12-3.05 (m, 2H), 2.91-2.85 (m, 1H), 2.81 (td,J= 12.9, 4.1 Hz, 1H), 2.72 (ddd,J= 16.7, 13.5, 5.1 Hz, 1H), 2.14-2.09 (m, 1H), 1.87 (dt,J= 14.4, 6.7 Hz, 2H), 1.51-1.41 (m, 13H), 1.37-1.23 (m, 12H).

[0193]

[0194] tert-Butyl(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy-y)ethyl)carbamate, 5d: The title compound was synthesized using general method B and obtained as an off-white solid in 86% yield.

[0195] 1 H NMR (600 MHz, CDCl3) δ 7.98 (s, 1H), 7.69 (dd,J= 8.4, 7.3 Hz, 1H), 7.49 (dd,J= 7.3, 0.7 Hz, 1H), 7.27-7.25 (m, 1H), 5.04 (bs, 1H), 4.96 (dd,J= 12.6, 5.4 Hz, 1H), 4.34 (t,J= 4.8 Hz, 2H), 3.92-3.89 (m, 2H), 3.66 (t,J= 5.2 Hz, 2H), 3.37-3.30 (m, 2H), 2.93-2.87 (m, 1H), 2.83 (qd,J= 12.7, 4.0 Hz, 1H), 2.73 (ddd,J= 16.9, 13.6, 5.0 Hz, 1H), 2.16-2.10 (m, 1H), 1.42 (s, 9H).

[0196]

[0197] tert-Butyl (2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethyl)carbamate, 5e: The title compound was synthesized using general method B and obtained as an off-white solid in 64% yield.

[0198] 1 H NMR (600 MHz, CDCl3) δ 8.20 (s, 1H), 7.68 (dd,J= 8.3, 7.4 Hz, 1H), 7.48 (d,J= 7.3 Hz, 1H), 7.27-7.25 (m, 1H, mixed with CDCl3), 5.03 (s, 1H), 4.95 (dd,J= 12.4, 4.4 Hz, 1H), 4.37-4.34 (m, 2H), 3.96-3.93 (m, 2H), 3.78 (t,J= 4.5 Hz, 2H), 3.63 (t,J= 4.6 Hz, 2H), 3.57-3.52 (m, 2H), 3.33-3.27 (m, 2H), 2.91-2.86 (m, 1H), 2.81 (ddd,J= 24.5, 12.4, 3.5 Hz, 1H), 2.77-2.69 (m, 1H), 2.15-2.10 (m, 1H), 1.43 (s, 9H).

[0199]

[0200] tert-Butyl (2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-oxy)-ethoxy)ethoxy)ethoxy)ethyl)carbamate, 5f: The title compound t was synthesized using general method B and obtained as an off-white solid in 68% yield.

[0201] 1H NMR (600 MHz, CDCl3) δ 8.19 (s, 1H), 7.67 (dd,J= 8.5, 7.3 Hz, 1H), 7.47 (d,J= 7.1 Hz, 1H), 7.27 (d,J= 8.5 Hz, 1H), 5.06 (s, 1H), 4.95 (dd,J= 12.5, 5.4 Hz, 1H), 4.36 (t,J= 4.8 Hz, 2H), 3.96-3.94 (m, 2H), 3.81-3.78 (m, 2H), 3.68-3.65 (m, 2H), 3.65-3.58 (m, 4H), 3.53 (t,J= 5.2 Hz, 2H), 3.33-3.27 (m, 2H), 2.92-2.86 (m, 1H), 2.86-2.77 (m, 1H), 2.73 (ddd,J= 16.8, 13.6, 4.9 Hz, 1H), 2.15-2.09 (m, 1H), 1.43 (s, 9H).

[0202] C. General method for NH-Boc deprotection: To a stirred solution of Boc-amine (1.00 equiv) in anhydrous CH2Cl2, trifluoroacetic acid (10.00 equiv) was added dropwise at 0°C. The reaction mixture was stirred at 25°C for 1 h. After completion of the reaction, the mixture was concentrated in vacuo, and the residue was co-evaporated with toluene (twice), affording the desired product as a TFA salt. The crude material was used in the next step without further purification.

[0203] D. General method for the synthesis of 6a-f: To a stirred solution of nutrylic acid (1.20 equiv) in anhydrous DMF, HATU (1.50 equiv) and DIPEA (5.00 equiv) were added at 25°C. The reaction mixture was stirred at the same temperature for 30 min, after which a solution of the TFA salt or the free amine (1.00 equiv) in anhydrous DMF was added dropwise. The reaction mixture was stirred at 25°C for 16 h. After the reaction was completed, the mixture was diluted with water and ethyl acetate and stirred vigorously. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with a saturated aqueous solution of LiCl and brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.

[0204]

[0205] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5 dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)acetamide, 6a: The title compound was synthesized using General Method C followed by General Method D. The crude material was purified by biotage on silica gel column chromatography eluting with methanol / DCM. A second purification was performed by prep-HPLC and the product was obtained as an off-white solid in 28% yield.

[0206] 1H NMR (600 MHz, CD3OD) δ 7.75 (dd, J = 8.5, 7.3 Hz, 1H), 7.57 (dd, J = 8.3, 3.1 Hz, 1H), 7.42 (t, J = 7.8 Hz, 2H), 7.13 (d, J= 8.4 Hz, 2H), 7.07 (d, J = 8.2 Hz, 2H), 7.02 (dd, J = 8.4, 1.5 Hz, 2H), 6.94 (d, J = 8.0 Hz, 2H), 6.66 (m, 2H), 5.74 (d, J = 10.1 Hz, 1H), 5.58-5.53 (m, 1H), 5.09 (dd, J = 12.5, 5.5 Hz, 1H), 4.73 (p, J = 6.0 Hz, 1H), 4.62 (s, 3H), 4.21 (t, J = 6.0 Hz, 2H), 4.00-3.88 (m, 1H), 3.87 (s, 3H), 3.86-3.73 (m, 3H), 3.52 (m, 1H), 3.41 (m, 1H), 3.24-3.19 (m, 1H), 3.07-3.01 (m, 2H), 2.89-2.78 (m, 1H), 2.75-2.65 (m, 2H), 2.08 (m, 1H), 1.86 (q, J = 6.7 Hz, 2H), 1.57 (m, 5H), 1.38-1.32 (m, 6H).

[0207] 13 C NMR (151 MHz, CD3OD) δ 174.7, 174.6, 171.6, 171.6, 169.7, 168.7, 167.5, 167.3, 165.2, 163.4, 158.6, 158.0, 155.7, 138.0, 137.4, 136.3, 135.1, 134.3, 133.2, 130.7, 130.0, 129.1, 129.0, 120.5, 118.1, 116.4, 113.4, 106.5, 101.2, 72.4, 71.8, 70.3, 70.1, 56.2, 50.6, 50.4, 50.3, 48.1, 43.2, 40.1, 40.1, 32.2, 29.8, 29.5, 24.2, 23.7, 22.5, 22.4.

[0208]

[0209] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(8-((2-(2,6-dioxo-opiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl)acetamide, 6b: The title compound was synthesized using General Method C followed by General Method D. The crude material was purified by biotage on silica gel column chromatography, eluting with methanol / DCM. A second purification was performed by preparative HPLC, and the product was obtained as an off-white solid in 24% yield.

[0210] 1H NMR (600 MHz, CD3OD) δ 7.78-7.74 (m, 1H), 7.58 (dd,J= 8.4, 1.3 Hz, 1H), 7.45-7.41 (m, 2H), 7.15-7.12 (m, 2H), 7.08 (d,J= 7.7 Hz, 2H), 7.03 (d,J= 8.3 Hz, 2H), 6.94 (d,J= 8.0 Hz, 2H), 6.67 (dd,J= 8.4, 2.2 Hz, 1H), 6.65 (d,J= 2.3 Hz, 1H), 5.75 (d,J= 10.1 Hz, 1H), 5.56 (d,J= 10.1 Hz, 1H), 5.09 (dd,J= 12.7, 5.5 Hz, 1H), 4.73 (p,J= 6.1 Hz, 1H), 4.22 (t,J= 6.3 Hz, 2H), 3.91 (dd,J= 16.2, 3.5 Hz, 1H), 3.88 (s, 3H), 3.85-3.76 (m, 3H), 3.56-3.49 (m, 1H), 3.43-3.37 (m, 1H), 3.16 (t,J= 7.0 Hz, 2H), 3.10-2.99 (m, 2H), 2.86 (ddd,J= 19.0, 13.9, 5.3 Hz, 1H), 2.78-2.66 (m, 2H), 2.10 (dd,J= 10.1, 4.7 Hz, 1H), 1.84 (dt,J= 14.0, 6.4 Hz, 2H), 1.50 (dq,J= 28.7, 7.3 Hz, 4H), 1.41-1.31 (m, 12H).

[0211] 13C NMR (151 MHz, CD3OD) δ 174.6, 171.6, 169.6, 168.7, 167.4, 165.0, 163.2, 158.6, 158.1, 155.8, 138.0, 137.6, 136.5, 135.2, 134.2, 133.1, 130.7, 130.0, 129.1, 129.0, 120.6, 118.1, 116.3, 113.8, 106.5, 101.2, 72.4, 72.1, 70.5, 70.1, 56.2, 50.6, 50.4, 50.3, 48.2, 43.2, 40.4, 32.2, 30.3, 30.1, 30.0, 27.7, 26.8, 23.7, 22.5, 22.4.

[0212]

[0213] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(11-((2-(2,6-dioxop-erydin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)undecyl)acetamide, 6c: The title compound was synthesized using General Method C followed by General Method D. The crude material was purified by biotage on a C-18 silica gel column chromatography, eluted with acetonitrile / deionized water. A second purification was performed by prep-HPLC and the product was obtained as an off-white solid in 48% yield.

[0214] 1H NMR (600 MHz, CD3OD) δ 7.77-7.73 (m, 1H), 7.59 (d,J= 8.3 Hz, 1H), 7.44-7.40 (m, 2H), 7.13 (d,J= 8.5 Hz, 2H), 7.08 (d,J= 8.8 Hz, 2H), 7.03 (d,J= 8.5 Hz, 2H), 6.95 (d,J= 8.1 Hz, 2H), 6.67 (dd,J= 8.4, 2.3 Hz, 1H), 6.65 (d,J= 2.2 Hz, 1H), 5.75 (d,J= 10.1 Hz, 1H), 5.56 (d,J= 10.1 Hz, 1H), 5.09 (dd,J= 12.4, 5.5 Hz, 1H), 4.73 (p,J= 6.0 Hz, 1H), 4.22-4.19 (m, 2H), 3.91 (d,J= 16.1 Hz, 1H), 3.88 (s, 3H), 3.85-3.76 (m, 3H), 3.53 (dt,J= 13.9, 5.2 Hz, 1H), 3.44-3.36 (m, 1H), 3.14 (t,J= 7.1 Hz, 2H), 3.10-3.00 (m, 2H), 2.86 (ddd,J= 18.3, 14.2, 5.4 Hz, 1H), 2.77-2.66 (m, 2H), 2.13-2.07 (m, 1H), 1.88-1.81 (m, 2H), 1.56-1.43 (m, 4H), 1.42-1.25 (m, 18H).

[0215] 13C NMR (151 MHz, CD3OD) δ 174.6, 171.5, 169.6, 168.7, 167.3, 165.0, 163.2, 158.5, 158.1, 155.83, 137.93, 137.58, 136.47, 135.13, 134.19, 133.09, 130.72, 129.96, 129.08, 129.00, 120.52, 118.12, 116.28, 113.82, 106.43, 101.23, 72.42, 72.07, 70.51, 70.07, 56.16, 50.54, 50.40, 50.23, 48.17, 43.16, 40.45, 32.20, 30.57, 30.49, 30.36, 30.33, 30.31, 29.99, 27.89, 26.91, 23.68, 22.49, 22.44.

[0216]

[0217] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl))oxy)ethoxy)ethyl)acetamide, 6d: The title compound was synthesized using General Method C followed by General Method D. The crude material was purified by biotage on amine column chromatography, eluting with methanol / DCM. A second purification was performed by preparative HPLC, and the product was obtained as an off-white solid in 28% yield.

[0218] 1H NMR (600 MHz, CD3OD) δ 7.79 (dd, J = 8.5, 7.3 Hz, 1H), 7.59 (dd, J = 8.3, 2.2 Hz, 1H), 7.49-7.44 (m, 2H), 7.16 (d, J = 8.5 Hz, 2H), 7.12-7.09 (m, 2H), 7.04 (d, J = 8.4 Hz, 2H), 6.96 (d, J = 8.0 Hz, 2H), 6.71-6.67 (m, 2H), 5.82 (d, J = 10.0 Hz, 1H), 5.64 (t, J = 9.2 Hz, 1H), 5.10 (dd, J = 12.5, 5.3 Hz, 1H), 4.77 (td, J = 5.9, 2.3 Hz, 1H), 4.34 (t, J = 4.0 Hz, 2H), 3.94-3.81 (m, 5H), 3.83-3.73 (m, 2H), 3.65 (t, J = 5.2 Hz, 2H), 3.41 (m, 3H), 3.05 (m, 2H), 2.89-2.80 (m, 1H), 2.76-2.66 (m, 2H), 2.09 (m, 1H), 1.39 (dd, J = 6.0, 1.1 Hz, 3H), 1.37-1.28 (m, 6H).

[0219] 13 C NMR (151 MHz, CD3OD) δ 174.6, 174.6, 171.5, 169.9, 168.5, 167.7, 167.4, 165.1, 163.2, 158.6, 157.8, 155.9, 138.1, 137.6, 136.6, 136.5, 135.1, 134.2, 133.2, 130.8, 130.0, 129.1, 129.0, 120.8, 118.3, 116.8, 106.4, 101.2, 72.4, 72.1, 70.6, 70.3, 70.2, 70.0, 56.2, 50.5, 50.3, 48.1, 43.2, 40.4, 32.2, 32.2, 23.6, 22.5, 22.4.

[0220]

[0221] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(2-(2-(2-((2-(2,6-dioxo-opiperidin-3-yl))-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)eto-yl)acetamide, 6e: The title compound was synthesized using General Method C followed by General Method D. The crude material was purified by biotage on C-18 silica gel column chromatography, eluting with acetonitrile / deionized water. A second purification was performed by prep-HPLC and the product was obtained as an off-white solid in 30% yield.

[0222] 1H NMR (600 MHz, CD3OD) δ 7.79-7.75 (m, 1H), 7.58 (dd,J= 8.4, 2.7 Hz, 1H), 7.48-7.45 (m, 2H), 7.13 (d,J= 8.4 Hz, 2H), 7.07 (dd,J= 8.8, 1.6 Hz, 2H), 7.03 (dd,J= 8.5, 2.3 Hz, 2H), 6.94 (d,J= 8.0 Hz, 2H), 6.66 (dd,J= 8.3, 2.2 Hz, 1H), 6.64 (d,J= 2.3 Hz, 1H), 5.74 (d,J= 10.1 Hz, 1H), 5.56 (d,J= 10.1 Hz, 1H), 5.08 (ddd,J= 12.9, 5.6, 1.5 Hz, 1H), 4.72 (p,J= 6.0 Hz, 1H), 4.61 (bs, 2H), 4.37 (t,J= 4.4 Hz, 2H), 3.92-3.89 (m, 3H), 3.87 (s, 3H), 3.84-3.74 (m, 5H), 3.63-3.60 (m, 2H), 3.52 (t,J= 5.4 Hz, 2H), 3.41-3.32 (m, 2H), 3.07-2.97 (m, 2H), 2.89-2.81 (m, 1H), 2.77-2.64 (m, 2H), 2.11-2.06 (m, 1H), 1.37 (d,J= 6.0 Hz, 3H), 1.34 (d,J= 6.0 Hz, 3H).

[0223] 13 C NMR (151 MHz, CD3OD) δ 174.7, 174.6, 171.5, 169.9, 168.6, 167.4, 165.0, 163.2, 158.6, 157.8, 155.8, 138.0, 137.6, 136.5, 135.2, 134.2, 133.1, 130.7, 130.0, 129.1, 129.0, 120.9, 118.3, 116.8, 113.8, 106.4, 101.2, 72.4, 72.1, 71.3, 70.5, 70.4, 70.1, 56.2, 50.6, 50.5, 50.2, 48.1, 43.2, 40.5, 32.2, 23.7, 22.5, 22.4.

[0224]

[0225] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl))-1,3-dioxo)isoindolin-4-yl)oxy))ethoxy)ethoxy)-ethoxy)ethyl)-acetamide, 6f: The title compound was synthesized using General Method C followed by General Method D. The crude material was purified by biotage on C-18 silica gel column chromatography by eluting with acetonitrile / deionized water. The second purification was performed by preparative HPLC, and the product was obtained as an off-white solid in 20% yield.

[0226] 1H NMR (600 MHz, CD3OD) δ 7.77-7.73 (m, 1H), 7.58 (dd,J= 8.4, 1.8 Hz, 1H), 7.47-7.43 (m, 2H), 7.15-7.12 (m, 2H), 7.10-7.07 (m, 2H), 7.04-7.01 (m, 2H), 6.94 (d,J= 8.1 Hz, 2H), 6.67 (dd,J= 8.3, 2.5 Hz, 1H), 6.65 (d,J= 2.3 Hz, 1H), 5.75 (d,J= 10.1 Hz, 1H), 5.56 (d,J= 10.7 Hz, 1H), 5.08 (dd,J= 12.8, 5.4 Hz, 1H), 4.73 (p,J= 6.0 Hz, 1H), 4.39-4.35 (m, 2H), 3.96-3.90 (m, 3H), 3.88 (s, 3H), 3.86-3.75 (m, 5H), 3.67-3.63 (m, 2H), 3.63-3.60 (m, 2H), 3.57-3.54 (m, 2H), 3.49 (t,J= 5.4 Hz, 2H), 3.42-3.35 (m, 1H), 3.34-3.32 (m, 3H), 3.09-2.98 (m, 2H), 2.89-2.81 (m, 1H), 2.77-2.63 (m, 2H), 2.14-2.05 (m, 1H), 1.38 (d,J= 6.0 Hz, 3H), 1.34 (d,J= 6.0 Hz, 3H).

[0227] 13C NMR (151 MHz, CD3OD) δ 174.6, 171.5, 169.9, 168.6, 167.4, 167.3, 165.0, 163.2, 158.6, 157.8, 155.8, 138.0, 137.6, 136.5, 135.2, 134.2, 133.1, 130.7, 130.0, 129.1, 129.0, 120.9, 118.3, 116.7, 113.8, 106.5, 101.2, 72.4, 72.1, 72.0, 71.6, 71.3, 70.5, 70.5, 70.3, 70.1, 56.2, 50.5, 50.4, 50.2, 48.1, 43.2, 40.4, 32.2, 23.7, 22.5, 22.4.

[0228] Manufacturing Example 2-2. Synthesis of 10a-c:

[0229]

[0230] Preparation and conditions: (i) HATU, DIPEA, DMF, rt, 16 h; (ii) TFA, CH2Cl2, rt, 1 h; (iii) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0231]

[0232] tert-Butyl (2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide)ethyl)carbamate, 9a: The title compound was synthesized using General Method D. The crude material was purified by biotage on silica gel column chromatography eluting with methanol / DCM to give the product as a white solid in 48% yield.

[0233] 1H NMR (600 MHz, DMSO-d6) δ 11.12 (s, 1H), 8.05 (t, J = 5.9 Hz, 1H), 7.81 (dd, J = 8.5, 7.3 Hz, 1H), 7.50 (d, J = 7.2 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 6.87 (t, J = 5.8 Hz, 1H), 5.12 (dd, J = 12.9, 5.5 Hz, 1H), 4.76 (s, 2H), 3.16 (q, J = 6.4 Hz, 2H), 3.01 (q, J = 6.3 Hz, 2H), 2.93-2.83 (m, 1H), 2.63-2.55 (m, 1H), 2.55-2.52 (m, 1H), 2.06-2.00 (m, 1H), 1.36 (s, 9H).

[0234]

[0235] tert-Butyl (5-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide)pentyl)carbamate, 9b: The crude product of the title compound was purified by biotage on silica gel column chromatography eluting with methanol / DCM to give the product as a white solid in 58% yield.

[0236] 1H NMR (600 MHz, DMSO-d6) δ 11.12 (s, 1H), 7.94 (t, J = 5.9 Hz, 1H), 7.82 (dd, J = 8.5, 7.3 Hz, 1H), 7.49 (d, J = 7.2 Hz, 1H), 7.39 (d, J = 8.5 Hz, 1H), 6.77 (t, J = 5.6 Hz, 1H), 5.12 (dd, J = 12.9, 5.5 Hz, 1H), 4.76 (s, 2H), 3.12 (q, J = 6.7 Hz, 2H), 2.91-2.85 (m, 3H), 2.62-2.57 (m, 1H), 2.55-2.52 (m, 1H), 2.07-2.00 (m, 1H), 1.42 (p, J = 7.2 Hz, 2H), 1.38-1.32 (s, 11H), 1.23 (p, J = 7.5 Hz, 2H).

[0237]

[0238] tert-Butyl (8-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide)octyl)carbamate, 9c: The crude product of the title compound was purified by biotage on silica gel column chromatography eluting with methanol / DCM to give the product as a white solid in 52% yield.

[0239] 1H NMR (600 MHz, DMSO-d6) δ 11.12 (s, 1H), 7.93 (t, J = 5.8 Hz, 1H), 7.83-7.79 (m, 1H), 7.50 (d, J = 7.4 Hz, 1H), 7.39 (d, J = 8.9 Hz, 1H), 6.76 (t, J = 6.0 Hz, 1H), 5.12 (dd, J = 13.0, 5.5 Hz, 1H), 4.76 (s, 2H), 3.13 (q, J = 6.7 Hz, 2H), 2.91-2.85 (m, 3H), 2.63-2.57 (m, 2H), 2.54-2.51(m, 1H), 2.06-2.01 (m, 1H), 1.45-1.39 (m, 2H), 1.38-1.30 (m, 11H), 1.27-1.17 (m, 7H).

[0240]

[0241] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl))oxy)acetamido)ethyl)-acetamide, 10a: The title compound was synthesized using General Method C followed by General Method D. The crude material was purified by biotage on silica gel column chromatography by eluting with methanol / DCM. The second purification was performed by biotage on a C-18 silica gel column chromatography eluting with acetonitrile / deionized water to give the product as an off-white solid in 50% yield.

[0242] 1H NMR (600 MHz, CD3OD, δ) 7.81 (ddd,J= 8.6, 7.3, 1.3 Hz, 1H), 7.57 (dd,J= 8.5, 2.5 Hz, 1H), 7.55 (d,J= 7.3 Hz, 1H), 7.43 (d,J= 8.5 Hz, 1H), 7.15-7.12 (m, 2H), 7.08 (d,J= 8.7 Hz, 2H), 7.04-7.01 (m, 2H), 6.95 (d,J= 8.1 Hz, 2H), 6.68-6.64 (m, 2H), 5.74 (dd,J= 10.1, 2.9 Hz, 1H), 5.57 (dd,J= 10.1, 5.9 Hz, 1H), 5.16 (ddd,J= 12.7, 11.6, 5.6 Hz, 1H), 4.76-4.71 (m, 3H), 3.87 (d,J= 2.2 Hz, 4H), 3.85-3.71 (m, 3H), 3.53-3.39 (m, 3H), 3.39-3.32 (m, 3H), 3.09-2.96 (m, 2H), 2.92-2.82 (m, 1H), 2.78-2.69 (m, 2H), 2.15-2.09 (m, 1H), 1.38 (d,J= 6.0 Hz, 3H), 1.33 (dd,J= 6.0, 1.3 Hz, 3H).

[0243]

[0244] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(5-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl))oxy)acetamido)pentyl-l)acetamide, 10b: The title compound was synthesized using General Method C followed by General Method D. The crude material was purified by biotage on silica gel column chromatography eluting with methanol / DCM to give the product as an off-white solid in 56% yield.

[0245] 1H NMR (600 MHz, CD3OD) δ 7.81 (ddd,J= 8.6, 7.3, 1.4 Hz, 1H), 7.58 (dd,J= 8.3, 2.6 Hz, 1H), 7.54 (dd,J= 7.3, 1.3 Hz, 1H), 7.43 (dd,J= 8.4, 1.3 Hz, 1H), 7.15-7.12 (m, 2H), 7.10-7.07 (m, 2H), 7.05-7.01 (m, 2H), 6.95 (d,J= 8.0 Hz, 2H), 6.68-6.64 (m, 2H), 5.75 (dd,J= 10.1, 2.2 Hz, 1H), 5.57 (d,J= 10.1 Hz, 1H), 5.14 (ddd,J= 12.5, 5.5, 1.1 Hz, 1H), 4.77-4.70 (m, 3H), 3.92-3.74 (m, 5H), 3.82-3.75 (m, 2H), 3.56-3.49 (m, 1H), 3.43-3.34 (m, 1H), 3.37-3.32 (m, 2H), 3.17 (td,J= 7.0, 2.9 Hz, 2H), 3.10-2.99 (m, 2H), 2.92-2.82 (m, 1H), 2.78-2.67 (m, 2H), 2.16-2.09 (m, 1H), 1.58 (p,J= 6.9 Hz, 2H), 1.51 (p,J= 7.2 Hz, 2H), 1.42-1.36 (m, 5H), 1.34 (d,J= 6.0 Hz, 3H).

[0246] 13C NMR (151 MHz, CD3OD) δ 174.6, 171.4, 169.9, 169.7, 168.3, 167.8, 167.4, 165.0, 163.2, 158.6, 156.3, 155.9, 138.3, 137.6, 136.5, 134.9, 134.2, 133.1, 130.7, 130.0, 129.1, 129.0, 121.8, 119.4, 118.0, 113.8, 106.5, 101.2, 72.4, 72.1, 70.1, 69.5, 56.2, 50.6, 50.3, 48.2, 43.2, 40.3, 40.0, 32.2, 29.9, 29.8, 25.1, 23.6, 22.5, 22.4.

[0247]

[0248] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(8-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl))oxy) acetamido)octyl)- acetamide, 10c: The title compound was synthesized using General Method C followed by General Method D. The crude material was purified by biotage on silica gel column chromatography eluting with methanol / DCM to give the product as an off-white solid in 44% yield.

[0249] 1H NMR (600 MHz, CD3OD) δ 7.78 (dd,J= 8.4, 7.4 Hz, 1H), 7.56 (d,J= 8.4 Hz, 1H), 7.51 (dd,J= 7.2, 1.5 Hz, 1H), 7.40 (d,J= 8.5 Hz, 1H), 7.12-7.09 (m, 2H), 7.07-7.05 (m, 2H), 7.02-6.99 (m, 2H), 6.92 (d,J= 8.0 Hz, 2H), 6.65 (dd,J= 8.3, 2.3 Hz, 1H), 6.63 (d,J= 2.2 Hz, 1H), 5.73 (d,J= 10.1 Hz, 1H), 5.54 (d,J= 10.2 Hz, 1H), 5.11 (dd,J= 12.6, 5.4 Hz, 1H), 4.74-4.68 (m, 3H), 3.88 (d,J= 16.1 Hz, 1H), 3.85 (s, 3H), 3.78 (dd,J= 20.1, 16.7 Hz, 3H), 3.54-3.47 (m, 1H), 3.37 (ddd,J= 9.3, 7.1, 3.7 Hz, 1H), 3.11 (t,J= 7.1 Hz, 2H), 3.08-2.98 (m, 2H), 2.88-2.80 (m, 1H), 2.76-2.66 (m, 2H), 2.14-2.08 (m, 1H), 1.54 (p,J= 7.0 Hz, 2H), 1.43 (p,J= 7.0 Hz, 2H), 1.37-1.22 (m, 16H).

[0250] 13C NMR (151 MHz, CD3OD) δ 174.6, 171.4, 169.8, 169.7, 168.3, 167.8, 167.4, 165.0, 163.2, 158.6, 156.3, 155.9, 138.2, 137.6, 136.5, 134.9, 134.2, 133.1, 130.7, 130.0, 129.1, 129.0, 121.7, 119.3, 118.0, 113.9, 106.5, 101.3, 72.4, 72.1, 70.1, 69.4, 56.2, 50.6, 50.6, 50.3, 48.2, 43.2, 40.4, 40.1, 32.2, 30.3, 30.2, 27.8, 27.7, 23.6, 22.5, 22.4.

[0251] Manufacturing Example 2-3. Synthesis of 16a-c

[0252]

[0253] Formulations and conditions: (i) (COCl)2, DMSO, DIPEA, CH2Cl2, -78 ºC to -30 ºC, 1 h or PCC, Al2O3, CH2Cl2, rt, 3 h; (ii) Dimethyl (1-diazo-2-oxopropyl)phosphonate, K2CO3, CH3OH, rt, 12 h, (iii) CuI, PdCl2(PPh3)2, Et3N, DMF, 80 ºC, 16 h; (iv) TFA, CH2Cl2, rt, 1 h; (v) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0254] Synthesis of 12a: To a stirred solution of anhydrous DMSO (0.16 g, 2.16 mmol, 2.20 equiv) in anhydrous CH2Cl2 (2.00 mL) under a nitrogen atmosphere at -78°C was added dropwise oxalyl chloride (0.25 g, 1.97 mmol, 2.00 equiv). After stirring for 5 min, a solution of alcohol (0.20 g, 0.98 mmol, 1.00 equiv) in anhydrous CH2Cl2 (3.00 mL) was added, and the reaction mixture was stirred at -78°C for 15 min. Subsequently, N,N-diisopropylethylamine (0.63 g, 4.91 mmol, 5.00 equiv) was added dropwise. The temperature of the reaction mixture was increased to -30°C and stirred at the same temperature for 30 min. After completion of the reaction, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (15 mL) and washed with water (1 × 15 mL). The organic layer was washed with 5% aqueous NaHCO3 solution (1 × 15 mL), water (1 × 15 mL), and brine (1 × 15 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude material was used in the next step without further purification.

[0255] E. General method for the synthesis of 12b to c: Pyridinium chlorochromate (1.50 eq) was added to a stirred solution of alcohol (1.00 eq) in anhydrous CH2Cl2. Al2O3 (6.00 eq) was then added little by little over 15 minutes. The reaction mixture was stirred at 25°C for 2 hours. After completion of the reaction, it was filtered through Celite, washing with CH2Cl2. The filtrate was removed under reduced pressure, and the residue was dried under high vacuum to give the desired product. The crude material was used in the next step without further purification.

[0256] F. General method for the synthesis of 13a to c: To a stirred solution of aldehyde (1.00 equiv.) in anhydrous methanol was added K2CO3 (2.20 equiv.) and dimethyl(1-diazo-2-oxopropyl)phosphonate (1.20 equiv.) under a nitrogen atmosphere at 25°C. The reaction mixture was stirred at the same temperature for 12 h. After the reaction was complete, the solvent was removed under reduced pressure, and the residue was partitioned between diethyl ether and water. The aqueous layer was extracted with diethyl ether. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by flash column chromatography on silica gel, eluting with ethyl acetate / hexane, to give the desired product in 40-93% yield.

[0257]

[0258] tert-Butyl hexa-5-yn-1-ylcarbamate, 13a: The title compound was synthesized using general method F as a pale yellow liquid in 40% yield.

[0259] 1 H NMR (600 MHz, CDCl3) δ 4.55 (bs, 1H), 3.13 (t,J= 6.7 Hz, 2H), 2.21 (td,J= 6.8, 2.6 Hz, 2H), 1.94 (t,J= 2.6 Hz, 1H), 1.63-1.52 (m, 4H), 1.43 (s, 9H).

[0260]

[0261] tert-Butyl non-8-yn-1-ylcarbamate, 13b: The title compound was synthesized using general method F as a pale yellow liquid in 93% yield.

[0262] 1H NMR (600 MHz, CDCl3) δ 4.48 (bs, 1H), 3.10 (t,J= 7.1 Hz, 2H), 2.18 (td,J= 7.1, 2.7 Hz, 2H), 1.93 (t,J= 2.6 Hz, 1H), 1.55-1.49 (m, 2H), 1.48-1.42 (s, 11H), 1.42-1.36 (m, 2H), 1.35-1.28 (m, 4H).

[0263]

[0264] tert-Butyldodeca-11-yn-1-ylcarbamate, 13c: The title compound was synthesized using general method F as a white sticky solid in 66% yield.

[0265] 1 H NMR (600 MHz, CDCl3) δ 4.46 (bs, 1H), 3.08 (t,J= 7.3 Hz, 2H), 2.17 (td,J= 7.1, 2.6 Hz, 2H), 1.92 (t,J= 2.6 Hz, 1H), 1.54-1.48 (m, 2H), 1.47-1.41 (m, 11H), 1.40-1.33 (m, 2H), 1.27 (m, 10H).

[0266] G. General method for the synthesis of 15a-c: To a stirred solution of 2-(2,6-dioxopiperidin-3-yl)-4-iodoisoindoline-1,3-dione (1.00 equiv) in anhydrous DMF was added alkyne (1.20 equiv), CuI (0.20 equiv), and trimethylamine (1.20 equiv). The reaction mixture was degassed with N2, and PdCl2(PPh3)2 (0.10 equiv) was added. The reaction mixture was stirred at 80°C for 16 h. After completion of the reaction, it was cooled to room temperature and poured into saturated aqueous NH4Cl solution. The layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with saturated aqueous LiCl, brine, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by flash column chromatography on silica gel eluting with acetone / hexane to give the desired product in 50-75% yield.

[0267]

[0268] tert-Butyl(6-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)hexa-5-yn-1-yl)-carbamate, 15a: The title compound was synthesized using General Method G as a white solid in 50% yield.

[0269] 1 H NMR (600 MHz, DMSO-d6) δ 11.07 (s, 1H), 7.83-7.80 (m, 1H), 7.80-7.76 (m, 2H), 6.77 (m, 1H), 5.09 (dd,J= 12.9, 5.5 Hz, 1H), 2.96-2.89 (m, 2H), 2.85 (ddd,J= 17.2, 14.0, 5.5 Hz, 1H), 2.59-2.54 (m, 2H), 2.53-2.47 (m, 4H), 2.02 (m, 1H), 1.33 (s, 9H).

[0270]

[0271] tert-Butyl (9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)non-8-yn-1-yl) carbamate, 15b: The title compound was synthesized as a yellow solid in 64% yield using general method G.

[0272] 1H NMR (600 MHz, DMSO-d6) δ 11.09 (s, 1H), 7.82 (dd,J= 6.2, 2.2 Hz, 1H), 7.80-7.75 (m, 2H), 6.71 (t,J= 5.5 Hz, 1H), 5.10 (dd,J= 12.9, 5.5 Hz, 1H), 2.89-2.81 (m, 3H), 2.60-2.54 (m, 1H), 2.53-2.48 (m, 1H), 2.05-1.99 (m, 1H), 1.54 (p,J= 6 Hz, 2H), 1.45-1.38 (m, 2H), 1.36-1.16 (m, 17H).

[0273]

[0274] tert-Butyl(12-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)dodeca-11-yn-1-yl)carbamate, 15c: The title compound was synthesized as a yellow solid in 75% yield using general method G.

[0275] 1 H NMR (600 MHz, DMSO-d6) δ 11.09 (s, 1H), 7.82 (dd,J= 6.6, 1.9 Hz, 1H), 7.80-7.75 (m, 2H), 6.70 (t,J= 6 Hz, 1H), 5.10 (dd,J= 12.9, 5.5 Hz, 1H), 2.89-2.81 (m, 3H), 2.59-2.53 (m, 1H), 2.53-2.48 (m, 1H), 2.04-1.98 (m, 1H), 1.54 (p,J= 6 Hz, 2H), 1.42 (p,J= 6 Hz, 2H), 1.34-1.13 (m, 23H).

[0276]

[0277] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(6-(2-(2,6-dioxopipe-lysin-3-yl)-1,3-dioxoisoindolin-4-yl)hexa-5-yn-1-yl) acetamide, 16a: The title compound was synthesized using General Method C followed by General Method D. The crude material was purified by biotage on silica gel column chromatography eluting with methanol / DCM. A second purification was performed by biotage on C-18 silica gel column chromatography eluting with acetonitrile / deionized water to give the product as an off-white solid with 35% yield.

[0278] 1 H NMR (600 MHz, CD3OD) δ 7.83-7.78 (m, 1H), 7.77-7.72 (m, 2H), 7.58 (dd,J= 8.4, 3.7 Hz, 1H), 7.15-7.12 (m, 2H), 7.08 (d,J= 8.7 Hz, 2H), 7.05-7.01 (m, 2H), 6.95 (d,J= 7.8 Hz, 2H), 6.69-6.64 (m, 2H), 5.75 (d,J= 10.2 Hz, 1H), 5.57 (d,J= 10.1 Hz, 1H), 5.16 (ddd,J=12.5, 5.4, 2.8 Hz, 1H), 4.73 (p,J= 6.0 Hz, 1H), 3.99-3.77 (m, 7H), 3.56-3.49 (m, 1H), 3.45-3.35 (m, 1H), 3.26 (t,J= 6.7 Hz, 2H), 3.10-3.02 (m, 2H), 2.91-2.81 (m, 1H), 2.79-2.69 (m, 2H), 2.55 (t,J= 6.7 Hz, 2H), 2.16-2.08 (m, 1H), 1.79-1.72 (m, 2H), 1.71-1.63 (m, 2H), 1.38 (d,J=6.0 Hz, 3H), 1.34 (dd,J= 6.0, 1.4 Hz, 3H).

[0279] 13 C NMR (151 MHz, CD3OD) δ 174.6, 171.5, 169.8, 168.0, 167.6, 167.3, 165.0, 163.2, 158.6, 155.8, 139.5, 137.5, 136.4, 135.3, 134.2, 133.8, 133.1, 131.9, 130.7, 130.0, 129.1, 129.0, 123.4, 122.4, 113.7, 106.5, 101.3, 99.6, 77.4, 72.4, 72.0, 70.1, 56.2, 50.6, 50.3, 48.1, 43.2, 39.9, 32.2, 29.4, 26.6, 23.6, 22.5, 22.4, 20.0.

[0280]

[0281] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)non-8-yn-1-yl) acetamide, 16b: The title compound was synthesized using General Method C followed by General Method D. The crude material was purified by biotage on silica gel column chromatography, eluting with methanol / DCM. A second purification was performed by biotage on C-18 silica gel column chromatography, eluting with acetonitrile / deionized water, to give the product as an off-white solid with 28% yield.

[0282] 1H NMR (600 MHz, CD3OD) δ 7.80 (dd,J= 6.4, 2.1 Hz, 1H), 7.76-7.72 (m, 2H), 7.58 (dd,J= 8.4, 2.2 Hz, 1H), 7.14 (d,J= 8.4 Hz, 2H), 7.08 (d,J= 8.8 Hz, 2H), 7.03 (d,J= 7.1 Hz, 2H), 6.94 (d,J= 8.0 Hz, 2H), 6.67 (ddd,J= 8.4, 2.3, 0.9 Hz, 1H), 6.65 (d,J= 2.2 Hz, 1H), 5.75 (d,J= 10.1 Hz, 1H), 5.56 (d,J= 10.1 Hz, 1H), 5.14 (dd,J= 12.7, 5.5 Hz, 1H), 4.73 (p,J= 6.0 Hz, 1H), 3.90 (dd,J= 16.1, 3.1 Hz, 1H), 3.88 (s, 3H), 3.85-3.76 (m, 3H), 3.55-3.49 (m, 1H), 3.39 (m, 1H), 3.16 (t,J= 7.0 Hz, 2H), 3.10-2.99 (m, 2H), 2.91-2.83 (m, 1H), 2.78-2.67 (m, 2H), 2.52 (t,J= 6.8 Hz, 2H), 2.13 (m, 1H), 1.68-1.62 (m, 2H), 1.59-1.53 (m, 2H), 1.50 (p,J= 7.1 Hz, 2H), 1.40-1.32 (m, 10H).

[0283] 13C NMR (151 MHz, CD3OD) δ 174.6, 171.5, 169.7, 168.1, 167.5, 167.4, 165.0, 163.2, 158.6, 155.8, 139.5, 137.6, 136.5, 135.3, 134.2, 133.1, 131.9, 130.7, 130.0, 129.1, 129.0, 123.3, 122.6, 113.8, 106.5, 101.3, 100.1, 77.1, 72.5, 72.1, 70.1, 56.2, 50.6, 50.2, 48.2, 43.2, 40.4, 32.2, 30.2, 29.8, 29.6, 29.3, 27.8, 23.6, 22.5, 22.4, 20.3.

[0284]

[0285] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(12-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) dodeca-11-yn-1-yl) acetamide, 16c: The title compound was synthesized using General Method C followed by General Method D. The crude material was purified by biotage on silica gel column chromatography eluting with methanol / DCM. The second purification was performed by biotage on a C-18 silica gel column chromatography eluting with acetonitrile / deionized water to give the product as an off-white solid in 42% yield.

[0286] 1H NMR (600 MHz, CD3OD) δ 7.77 (dt,J= 6.3, 2.1 Hz, 1H), 7.74-7.69 (m, 2H), 7.56 (d,J= 8.4 Hz, 1H), 7.13-7.10 (m, 2H), 7.07-7.05 (m, 2H), 7.02-6.99 (m, 2H), 6.92 (d,J= 8.0 Hz, 2H), 6.65 (dd,J= 8.4, 2.3 Hz, 1H), 6.63 (d,J= 2.3 Hz, 1H), 5.73 (d,J= 10.1 Hz, 1H), 5.54 (d,J= 10.1 Hz, 1H), 5.11 (dd,J= 12.6, 5.5 Hz, 1H), 4.71 (p,J= 6.0 Hz, 1H), 3.88 (d,J= 16.1 Hz, 1H), 3.85 (s, 3H), 3.84-3.74 (m, 3H), 3.50 (dt,J= 13.7, 5.2 Hz, 1H), 3.41-3.34 (m, 1H), 3.11 (t,J= 7.1 Hz, 2H), 3.07-2.98 (m, 2H), 2.88-2.80 (m, 1H), 2.76-2.65 (m, 2H), 2.49 (t,J= 6.9 Hz, 2H), 2.13-2.07 (m, 1H), 1.66-1.59 (m, 2H), 1.55-1.49 (m, 2H), 1.47-1.39 (m, 2H), 1.38-1.25 (m, 16H).

[0287] 13C NMR (151 MHz, CD3OD) δ 174.6, 171.4, 169.6, 168.1, 167.5, 167.4, 165.0, 163.2, 158.6, 155.8, 139.5, 137.6, 136.4, 135.3, 134.2, 133.8, 133.1, 131.9, 130.7, 130.0, 129.1, 129.0, 123.3, 122.6, 113.8, 106.5, 101.2, 100.2, 77.1, 72.4, 72.0, 70.1, 56.2, 50.6, 50.2, 48.2, 43.2, 40.4, 32.2, 30.5, 30.5, 30.4, 30.3, 30.2, 29.8, 29.4, 27.9, 23.6, 22.5, 22.4, 20.4.

[0288] Manufacturing Example 2-4. Synthesis of Compounds 17 to 21

[0289]

[0290] Manufacturing Example 2-4-1. Synthesis of Compound 17 (2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)acetamide)

[0291]

[0292] Preparation and conditions: (i) DIPEA, NMP, 90°C, 17 h; (ii) TFA, CH2Cl2, rt, 1 h; (iii) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0293]

[0294] tert-Butyl (8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)carbamate: To a stirred solution of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindolin-1,3-dione (1.00 equiv.) and tert-butyl (8-aminooctyl)carbamate (1.10 equiv.) in anhydrous NMP was added DIPEA (2.00 equiv.). The reaction mixture was stirred at 90 °C for 17 h. After the reaction was completed, the mixture was diluted with water and ethyl acetate and extracted with ethyl acetate. The combined organic layers were washed with 10% citric acid, aqueous NaHCO3 solution, water and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography on silica gel (30% acetone / hexane) to give the desired product in 64% yield.

[0295] 1 H NMR (600 MHz, CD3OD) δ 7.55 (dd,J= 8.6, 7.1 Hz, 1H), 7.04 (dd,J= 7.8, 2.4 Hz, 2H), 5.06 (dd,J= 12.5, 5.5 Hz, 1H), 3.34 (p,J= 1.7 Hz, 2H), 3.29 (p,J= 1.6 Hz, 1H), 3.01 (t,J= 7.1 Hz, 2H), 2.90-2.82 (m, 1H), 2.77-2.67 (m, 2H), 2.14-2.08 (m, 1H), 1.67 (p,J= 7.1 Hz, 2H), 1.50-1.30 (m, 18H).

[0296]

[0297] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)acetamide: The title compound was synthesized using General Method C followed by General Method D and obtained as a yellow solid in 51% yield.

[0298] 1 H NMR (600 MHz, CD3OD) δ 7.94 (t,J= 5.7 Hz, 1H), 7.60 (dd,J= 8.4, 1.5 Hz, 1H), 7.55 (dd,J= 8.6, 7.2 Hz, 1H), 7.21-7.13 (m, 2H), 7.13-7.08 (m, 2H), 7.07-7.01 (m, 4H), 6.96 (d,J= 8.1 Hz, 2H), 6.73-6.67 (m, 2H), 5.83 (d,J= 10.2 Hz, 1H), 5.63 (d,J= 10.3 Hz, 1H), 5.05 (dd,J= 12.5, 5.5 Hz, 1H), 4.80-4.73 (m, 1H), 3.96-3.76 (m, 7H), 3.60-3.49 (m, 1H), 3.45-3.39 (m, 1H), 3.34-3.32 (m, 2H), 3.18-3.13 (m, 2H), 3.11-3.01 (m, 2H), 2.90-2.80 (m, 1H), 2.78-2.66 (m, 2H), 2.13-2.06 (m, 1H), 1.66 (p,J= 7.1 Hz, 2H), 1.57-1.24 (m, 16H). LRMS (ESI)m / z([M+H] + ) cacld for C 53 H 59 Cl2N8O9: 1021.4, found: 1021.3.

[0299] Manufacturing Example 2-4-2. Synthesis of Compound 18 (2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)phenyl)but-3-yn-1-yl)acetamide)

[0300]

[0301] Preparation and conditions: (i) CuI, PdCl2(PPh3)2, Et3N, DMF, 80°C, 3 h; (ii) MsCl, NEt3, CH2Cl2, 0°C->rt, 25 h; (iii) K2CO3, DMF, 60°C, 4 h; (iv) TFA, CH2Cl2, rt, 1 h; (v) nutlinic acid, HATU, DIPEA, DMF, rt, 16 h.

[0302]

[0303] tert-Butyl (4-(4-(hydroxymethyl)phenyl)but-3-yn-1-yl)carbamate: CuI (0.20 equiv) and Et3N (1.20 equiv) were added to a stirred solution of (4-iodophenyl)methanol (1.00 equiv) dissolved in anhydrous DMF. The reaction mixture was purged with N2, and PdCl2(PPh3)2 (0.10 equiv) was added. The reaction mixture was stirred at 80°C for 16 h. After the reaction was completed, the reaction mixture was cooled to room temperature and poured into a saturated aqueous NH4Cl solution. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with a saturated aqueous LiCl solution and brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The product was purified by column chromatography on C-18 silica gel (10%→100% acetonitrile / water containing 0.1% formic acid) to obtain the desired product in 34% yield.

[0304] 1H NMR (600 MHz, CDCl3) δ 7.42-7.38 (m, 2H), 7.31-7.28 (m, 2H), 4.87 (s, 1H), 4.69 (s, 2H), 3.36 (d,J= 7.3 Hz, 2H), 2.60 (t,J= 6.5 Hz, 2H), 1.46 (s, 9H).

[0305]

[0306] tert-Butyl(4-(4-(chloromethyl)phenyl)but-3-yn-1-yl)carbamate: tert-Butyl(4-(4-(hydroxymethyl)phenyl)but-3-yn-1-yl)carbamate (1.00 equiv) was dissolved in CH2Cl2 under N2 and cooled to 0°C. MsCl (1.20 equiv) and Et3N (1.50 equiv) were added, and the reaction mixture was stirred for 2 hours and warmed to room temperature. After the reaction was completed, the mixture was diluted with water and CH2Cl2 and extracted with CH2Cl2. The combined organic layers were dried over MgSO4, filtered, and concentrated under reduced pressure. The product was purified by column chromatography on silica gel (0%→100% ethyl acetate / hexane) to give the desired product in 63% yield.

[0307] 1 H NMR (600 MHz, CDCl3) δ 7.39-7.36 (m, 2H), 7.32-7.29 (m, 2H), 4.84 (s, 1H), 4.55 (s, 2H), 3.35 (d,J= 6.5 Hz, 2H), 2.59 (t,J= 6.5 Hz, 2H), 1.44 (s, 9H).

[0308]

[0309] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)phenyl) but-3-yn-1-yl)acetamide. The title compound was synthesized using General Method C followed by General Method D and was obtained as a white solid in a yield of 46%.

[0310] 1 H NMR (600 MHz, CD3OD) δ 7.74 (ddd,J= 8.7, 7.3, 1.4 Hz, 1H), 7.56 (d,J= 8.2 Hz, 1H), 7.51-7.43 (m, 4H), 7.42-7.39 (m, 2H), 7.14-7.11 (m, 2H), 7.09-7.06 (m, 2H), 7.02 (d,J= 8.2 Hz, 2H), 6.94 (d,J= 8.1 Hz, 2H), 6.68-6.64 (m, 2H), 5.74 (d,J= 10.1 Hz, 1H), 5.55 (d,J=10.1 Hz, 1H), 5.35 (s, 2H), 5.12 (dd,J= 12.8, 5.5 Hz, 1H), 4.72 (p,J= 6.0 Hz, 1H), 3.97 (dd,J= 16.2, 1.8 Hz, 1H), 3.92-3.74 (m, 6H), 3.49-3.36 (m, 3H), 3.03-2.96 (m, 2H), 2.90-2.81 (m, 1H), 2.77-2.68 (m, 2H), 2.61 (t,J= 6.7 Hz, 2H), 2.15-2.08 (m, 1H), 1.37-1.32 (m, 6H).

[0311] LRMS (ESI) m / z([M+H] + ) cacld for C 56 H 51 Cl2N7O 10 : 1052.3, found:1052.3.

[0312] Manufacturing Example 2-4-3. Synthesis of Compound 19 (2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)phenyl) butyl)acetamide

[0313]

[0314] Formulations and conditions: (i) H2, Pd / C, ethyl acetate, rt, 2 h; (ii) MsCl, NEt3, CH2Cl2, 0℃->rt, 20 h; (iii) K2CO3, DMF, 60°C, 4 h; (iv) TFA, CH2Cl2, rt, 1 h; (v) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0315]

[0316] tert-Butyl (4-(4-(hydroxymethyl)phenyl)butyl)carbamate: To a stirred solution of tert-butyl (4-(4-(hydroxymethyl)phenyl)but-3-yn-1-yl)carbamate (1.00 eq) in ethyl acetate was added 10% Pd / C (0.05 eq). The reaction mixture was hydrogenated at room temperature for 2 h. After completion of the reaction, the catalyst was removed by filtration through a pad of Celite, which was washed with ethyl acetate. The product was purified by column chromatography on C-18 silica gel (10%→100% acetonitrile / water containing 0.1% formic acid) to give a yield of 78%.

[0317] 1H NMR (600 MHz, DMSO-d6) δ 7.20 (d,J= 7.9 Hz, 2H), 7.14-7.11 (m, 2H), 6.80 (t,J= 5.8 Hz, 1H), 5.08 (s, 1H), 4.44 (d,J= 3.4 Hz, 2H), 2.92 (q,J= 6.7 Hz, 2H), 2.55-2.51 (m, 2H), 1.51 (p,J= 7.9 Hz, 2H), 1.36 (s, 11H).

[0318]

[0319] tert-Butyl(4-(4-(chloromethyl)phenyl)butyl)carbamate: tert-Butyl(4-(4-(hydroxymethyl)phenyl)butyl)carbamate (1.00 equiv) was dissolved in CH2Cl2 under N2 and cooled to 0°C. MsCl (1.20 equiv) and Et3N (1.50 equiv) were added, and the reaction mixture was stirred for 20 h and warmed to room temperature. After the reaction was completed, the mixture was diluted with water and CH2Cl2 and extracted with CH2Cl2. The combined organic layers were dried over MgSO4, filtered, and concentrated under reduced pressure. The product was purified by column chromatography on silica gel (0%→100% ethyl acetate / hexane) in a yield of 50%.

[0320] 1 H NMR (600 MHz, DMSO-d6) δ 7.35-7.31 (m, 2H), 7.21-7.17 (m, 2H), 6.80 (t,J= 5.8 Hz, 1H), 4.72 (s, 2H), 2.92 (q,J= 6.7 Hz, 2H), 2.56 (t,J= 7.7 Hz, 2H), 1.52 (p,J= 7.7 Hz, 2H), 1.36 (s, 11H).

[0321]

[0322] 4-((4-(4-aminobutyl)benzyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione: To a stirred solution of tert-butyl(4-(4-(chloromethyl)phenyl)butyl)carbamate (1.11 equiv) and 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (1.00 equiv) in anhydrous DMF was added K2CO3 (2.50 equiv). The reaction mixture was stirred at 60°C for 6 h. After the reaction was complete, the mixture was diluted with water and CH2Cl2. The combined organic layers were dried over MgSO4, filtered, and concentrated under reduced pressure. The product was purified by column chromatography on C-18 silica gel (10%→100% acetonitrile / water containing 0.1% formic acid) to obtain a yield of 44%.

[0323] 1 H NMR (600 MHz, DMSO-d6) δ 11.12 (s, 1H), 7.82 (dd,J= 8.5, 7.3 Hz, 1H), 7.59 (d,J= 8.6 Hz, 1H), 7.46 (d,J= 7.2 Hz, 1H), 7.40 (d,J= 7.9 Hz, 2H), 7.23 (d,J= 8.0 Hz, 2H), 6.80 (t,J= 5.8 Hz, 1H), 5.32 (s, 2H), 5.09 (dd,J= 12.9, 5.4 Hz, 1H), 2.95-2.83 (m, 4H), 2.61-2.51 (m, 4H), 2.06-2.00 (m, 1H).

[0324]

[0325] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)phenyl) butyl)acetamide. The title compound was synthesized using General Method C followed by General Method D and was obtained as a white solid in a yield of 49%.

[0326] 1 H NMR (600 MHz, CD3OD) δ 7.75-7.71 (m, 1H), 7.58 (dd,J= 8.3, 2.8 Hz, 1H), 7.49-7.39 (m, 4H), 7.23-7.19 (m, 2H), 7.16-7.12 (m, 2H), 7.10-7.06 (m, 2H), 7.05-7.01 (m, 2H), 6.94 (d,J= 8.0 Hz, 2H), 6.68-6.63 (m, 2H), 5.75 (d,J= 10.2 Hz, 1H), 5.57 (d,J= 10.1 Hz, 1H), 5.32 (s, 2H), 5.10 (dd,J= 12.5, 5.5 Hz, 1H), 4.73 (p,J= 6.0 Hz, 1H), 3.93-3.73 (m, 7H), 3.55-3.48 (m, 1H), 3.43-3.35 (m, 1H), 3.18 (t,J= 6.9 Hz, 2H), 3.08-2.96 (m, 2H), 2.89-2.81 (m, 1H), 2.77-2.67 (m, 2H), 2.63 (t,J= 7.5 Hz, 2H), 2.14-2.07 (m, 1H), 1.66-1.58 (m, 2H), 1.50 (p,J= 7.0 Hz, 2H), 1.39-1.32 (m, 6H).

[0327] LRMS (ESI) m / z([M+H] + ) cacld for C 56 H 55 Cl2N7O 10 : 1056.4, found: 1056.4.

[0328] Manufacturing Example 2-4-4. Synthesis of Compound 20 (2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)nonyl)acetamide)

[0329]

[0330] Formulations and conditions: (i) (Boc)2O, CH2Cl2, 0℃->rt, 3 h; (ii) PCC, Al2O3, CH2Cl2, rt, 3 h; (iii) Dimethyl (1-diazo-2-oxopropyl)phosphonate, K2CO3, CH3OH, rt, 4 h; (iv) CuI, PdCl2(PPh3)2, Et3N, DMF, 80 ºC; (v) H2, Pd / C, ethanol, rt, 63 h; (vi) TFA, CH2Cl2, rt, 1 h; (vii) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0331]

[0332] tert-Butyl(8-hydroxyoctyl)carbamate: To a stirred solution of 8-aminooctan-1-ol (1.00 equiv.) in anhydrous CH2Cl2 was added (Boc)2O (1.20 equiv.) at 0°C, and the reaction mixture was stirred at room temperature for 3 h. After the reaction was completed, the solvent was concentrated under reduced pressure. The product was purified by silica gel column chromatography (40% ethyl acetate / hexane) to give a 32% yield.

[0333] 1 H NMR (600 MHz, CDCl3) δ 4.49 (s, 1H), 3.64 (t,J= 6.6 Hz, 2H), 3.16-3.01 (m, 2H), 1.55 (dt,J= 8.0, 6.7 Hz, 3H), 1.44 (s, 11H), 1.38-1.28 (m, 8H).

[0334]

[0335] Tert-Butyl(8-oxooctyl)carbamate. To a stirred mixture of tert-butyl(8-hydroxyoctyl)carbamate (1.00 equiv.) and PCC (1.50 equiv.) in anhydrous CH2Cl2 was added Al2O3 (6.00 equiv.), and the mixture was stirred at room temperature under N2 for 3 h. After completion of the reaction, the reaction mixture was filtered over silica, and the solvent was concentrated under reduced pressure. The mixture was used in the next step without further purification.

[0336]

[0337] Tert-Butyl bi-8-yn-1-ylcarbamate. To a stirred mixture of tert-butyl (8-oxooctyl)carbamate in anhydrous CH3OH was added K2CO3 (2.20 equiv) and dimethyl (1-diazo-2-oxopropyl)phosphonate (1.20 equiv), and the mixture was stirred at room temperature for 4 h. After completion of the reaction, the reaction mixture was diluted with water and extracted with diethyl ether. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The mixture was used in the next step without further purification.

[0338]

[0339] tert-Butyl (9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)non-8-yn-1-yl)carbamate. tert-Butyl bi-8-yn-1-ylcarbamate (1.20 equiv.), CuI (0.20 equiv.), and Et3N (1.20 equiv.) were added to a stirred solution of 2-(2,6-dioxopiperidin-3-yl)-4-iodoisoindolin-1,3-dione in anhydrous DMF. The reaction mixture was stirred at 80°C for 3 h. After completion of the reaction, the reaction mixture was cooled to room temperature and poured into a saturated aqueous NH4Cl solution. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with a saturated aqueous brine solution, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The product was purified by column chromatography on silica gel (40% acetone / hexane) to obtain a yield of 54%.

[0340] 1 H NMR (600 MHz, CDCl3) δ 8.36 (s, 1H), 7.77 (dd,J= 7.3, 1.2 Hz, 1H), 7.69 (dd,J= 7.9, 1.2 Hz, 1H), 7.67-7.64 (m, 1H), 4.99 (dd,J= 12.5, 5.4 Hz, 1H), 4.60 (s, 1H), 3.11 (d,J= 6.3 Hz, 2H), 2.94-2.71 (m, 3H), 2.52 (t,J= 6.9 Hz, 2H), 2.16-2.11 (m, 1H), 1.65 (p,J= 6.5 Hz, 2H), 1.44 (s, 13H), 1.35 (dd,J= 8.0, 4.6 Hz, 4H).

[0341]

[0342] tert-Butyl (9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)nonyl)carbamate. To a stirred solution of tert-butyl (9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)non-8-yn-1-yl)carbamate (1.00 equiv.) in ethanol was added 10% Pd / C (0.01 equiv.). The reaction mixture was hydrogenated at 40°C for 63 h. The catalyst was removed by filtration through a pad of Celite, which was rinsed with ethyl acetate. The product was purified by column chromatography on C-18 silica gel (10%→100% acetonitrile / water containing 0.1% formic acid) in 54% yield.

[0343] 1 H NMR (600 MHz, CDCl3) δ 8.11 (s, 1H), 7.72 (dd,J= 7.4, 1.0 Hz, 1H), 7.63 (t,J= 7.5 Hz, 1H), 7.52 (dd,J= 7.7, 1.0 Hz, 1H), 4.98 (dd,J= 12.6, 5.4 Hz, 1H), 4.53 (s, 1H), 3.15-2.99 (m, 4H), 2.95-2.70 (m, 3H), 2.19-2.11 (m, 1H), 1.64 (p,J= 7.7 Hz, 2H), 1.49-1.27 (m, 21H).

[0344]

[0345] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)nonyl)acetamide. The title compound was synthesized using General Method C followed by General Method D and was obtained as a white solid in a yield of 51%.

[0346] 1H NMR (600 MHz, CD3OD) δ 7.95 (t,J= 5.7 Hz, 1H), 7.74-7.69 (m, 2H), 7.64-7.58 (m, 2H), 7.17-7.13 (m, 2H), 7.12-7.07 (m, 2H), 7.06-7.01 (m, 2H), 6.95 (d,J= 8.0 Hz, 2H), 6.70-6.66 (m, 2H), 5.79 (d,J= 10.2 Hz, 1H), 5.60 (d,J= 10.2 Hz, 1H), 5.13 (dd,J= 12.7, 5.5 Hz, 1H), 4.76 (p,J= 6.0 Hz, 1H), 3.96-3.74 (m, 6H), 3.54 (d,J= 13.6 Hz, 1H), 3.44-3.38 (m, 1H), 3.15 (t,J= 6.9 Hz, 2H), 3.12-3.00 (m, 4H), 2.91-2.83 (m, 1H), 2.79-2.69 (m, 2H), 2.15-2.09 (m, 1H), 1.66 (p,J= 7.4 Hz, 2H), 1.50-1.43 (m, 2H), 1.41-1.28 (m, 17H).

[0347] LRMS (ESI) m / z([M+H] + ) cacld for C 54 H 59 Cl2N7O9: 1020.4, found: 1020.4.

[0348] Manufacturing Example 2-4-5. Synthesis of Compound 21 (2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(2-((4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)benzyl )oxy)ethyl)acetamide)

[0349]

[0350] Formulations and conditions: (i) imidazole, TBSCl, THF, 0℃->rt, 12 h; (ii) PPh3, imidazole, I2, imidazole, Et2O / MeCN (3:1), rt, 1h; (iii) TBAI, KOH, THF, rt, 40 h; (iv) TBAF, THF, rt, 3 h; (v) MsCl, DIPEA, DCM, 0℃->rt, 16 h; (vi) NaHCO3, KI, DMF, 80 °C, 16 h; (vii) TFA, CH2Cl2, rt, 1 h; (viii) nutlin acid, HATU, DIPEA, DMF, rt, 16 h.

[0351]

[0352] (4-(((tert-Butyldimethylsilyl)oxy)methyl)phenyl)methanol. To a stirred solution of 1,4-phenylenedimethanol (1.00 equiv.) and imidazole (1.00 equiv.) in THF was added TBSCl (0.75 equiv.) at 0°C, and the reaction mixture was stirred at room temperature for 12 h. After completion of the reaction, the reaction mixture was poured onto brine and extracted with a hexane / ether (4:1) solution. The combined organic layers were dried over a minimum amount of CaCl2 and concentrated under reduced pressure. The product was purified by column chromatography on silica gel (10% ethyl acetate / hexane) in a yield of 39%.

[0353] 1 H NMR (600 MHz, CDCl3) δ 7.35-7.30 (m, 4H), 4.74 (s, 2H), 4.68 (s, 2H), 0.94 (s, 9H), 0.10 (s, 6H).

[0354]

[0355] tert-Butyl((4-(iodomethyl)benzyl)oxy)dimethylsilane. PPh3 (1.10 equiv) and imidazole (2.00 equiv) were dissolved in a 3:1 mixture of Et2O / ACN. The reaction mixture was stirred until complete dissolution. At this time, I2 was added, and vigorous stirring was continued until a yellow suspension was formed. A solution of (4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)methanol (1.00 equiv) was added to the mixture and stirred for 20 h. After completion of the reaction, the solvent was removed under vacuum. The mixture was diluted with hexane and washed with saturated NaHSO4. The product was purified by column chromatography on silica gel (5% ethyl acetate / hexane) in a yield of 47%.

[0356] 1 H NMR (600 MHz, CDCl3) δ 7.36-7.33 (m, 2H), 7.25 (d, J= 8.0 Hz, 2H), 4.70 (s, 2H), 4.47 (s, 2H), 0.94 (s, 9H), 0.10 (s, 6H).

[0357]

[0358] tert-Butyl (2-((4-(((tert-butyldimethylsilyl)oxy)methyl)benzyl)oxy)ethyl)carbamate. To a stirred solution of tert-butyl((4-(iodomethyl)benzyl)oxy)dimethylsilane (1.00 equiv.) and tert-butyl (2-hydroxyethyl)carbamate (1.50 equiv.) in anhydrous THF were added TBAI (0.20 equiv.) and KOH (2.00 equiv.). The reaction mixture was stirred at room temperature for 40 h. The solvent was removed under reduced pressure. The product was purified by column chromatography on silica gel (10% ethyl acetate / hexanes) to give the product in 83% yield.

[0359] 1H NMR (600 MHz, CDCl3) δ 7.32-7.27 (m, 4H), 4.90 (s, 1H), 4.73 (s, 2H), 4.50 (s, 2H), 3.53 (t,J= 5.1 Hz, 2H), 3.37-3.28 (m, 2H), 1.44 (s, 9H), 0.94 (s, 9H), 0.09 (s, 6H).

[0360]

[0361] tert-Butyl (2-((4-(hydroxymethyl)benzyl)oxy)ethyl)carbamate. To a stirred solution of tert-butyl (2-((4-(((tert-butyldimethylsilyl)oxy)methyl)benzyl)oxy)ethyl)carbamate (1.00 equiv.) in anhydrous THF was cooled to 0°C and TBAF (1 M in THF) (1.20 equiv.) was added dropwise. The reaction mixture was stirred at 0°C for 2 h. After completion of the reaction, the reaction was quenched with aqueous NH4Cl and extracted with ethyl acetate. The product was purified by column chromatography on silica gel (10%→30% ethyl acetate / hexane) in 82% yield.

[0362] 1 H NMR (600 MHz, CDCl3) δ 7.39-7.31 (m, 4H), 4.90 (s, 1H), 4.70 (s, 2H), 4.52 (s, 2H), 3.54 (t,J= 5.2 Hz, 2H), 3.34 (d,J= 5.5 Hz, 2H), 1.44 (s, 9H).

[0363]

[0364] tert-Butyl (2-((4-(chloromethyl)benzyl)oxy)ethyl)carbamate. To a stirred solution of tert-butyl (2-((4-(hydroxymethyl)benzyl)oxy)ethyl)carbamate (1.00 equiv) and DIPEA (0.20 equiv) in CH2Cl2 was added MsCl (2.00 equiv) dropwise at 0°C. The reaction mixture was stirred at 0°C for 1 h and warmed to room temperature for 16 h. The product was purified by column chromatography on silica gel (10% ethyl acetate / hexanes) in 95% yield.

[0365] 1 H NMR (600 MHz, CDCl3) δ 7.40 - 7.35 (m, 2H), 7.32 (d,J= 8.1 Hz, 2H), 4.89 (s, 1H), 4.59 (s, 2H), 4.52 (s, 2H), 3.54 (t,J= 5.2 Hz, 2H), 3.35 (d,J= 6.1 Hz, 2H), 1.44 (s, 9H).

[0366]

[0367] tert-Butyl (2-((4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)benzyl)oxy)ethyl)carbamate. To a stirred solution of 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (1.10 equiv.) dissolved in anhydrous DMF were added NaHCO3 (1.50 equiv.) and KI (1.00 equiv.). The reaction mixture was stirred at 80°C for 16 h. The product was purified by column chromatography on silica gel (40%→60% ethyl acetate / hexanes) in 57% yield.

[0368] 1H NMR (600 MHz, CDCl3) δ 8.21 (s, 1H), 7.63 (ddd,J= 8.5, 7.1, 1.2 Hz, 1H), 7.50-7.42 (m, 3H), 7.35 (d,J= 7.9 Hz, 2H), 7.28-7.19 (m, 2H), 4.97 (dd,J= 12.5, 5.4 Hz, 1H), 4.90 (d,J= 17.2 Hz, 1H), 4.51 (s, 2H), 3.54 (t,J= 5.1 Hz, 2H), 3.34 (s, 2H), 2.92-2.70 (m, 3H), 2.19-2.08 (m, 1H), 1.43 (s, 10H).

[0369]

[0370] 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(2-((4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)benzyl )oxy)ethyl)acetamide. The title compound was synthesized using General Method C followed by General Method D and was obtained as a white solid in a yield of 22%.

[0371] 1H NMR (600 MHz, CD3OD) δ = 7.71 (ddd,J=8.4, 7.4, 0.9, 1H), 7.54 (t,J=8.0 Hz, 1H), 7.49 (d,J=7.3 Hz, 2H), 7.45 (dd,J=8.5, 2.4 Hz, 1H), 7.43 (d,J=7.3 Hz, 1H), 7.35 (d,J=8.1 Hz, 2H), 7.12 (d,J=8.4 Hz, 2H), 7.06 (dd,J=8.8, 1.7 Hz, 2H), 7.00 (d,J=8.4 Hz, 2H), 6.91 (d,J=7.6 Hz, 2H), 6.64-6.61 (m, 2H), 5.74 (d,J=8.0 Hz, 1H), 5.56 (dd,J=10.3, 3.2 Hz, 1H), 5.32 (s, 2H), 5.11-5.06 (m, 1H), 4.71 (dd,J=12.2, 6.0 Hz, 1H), 4.49 (s, 2H), 3.91 (dd,J=16.2, 8.5 Hz, 1H), 3.84 (d,J=2.6 Hz, 3H), 3.83-3.71 (m, 3H), 3.51 (t,J=5.5 Hz, 2H), 3.49-3.44 (m, 1H), 3.41-3.30 (m, 5H), 2.97-2.92 (m, 2H), 2.86-2.78 (m, 1H), 2.74-2.64 (m, 2H), 2.10-2.04 (m, 1H), 1.34 (d,J=6.0 Hz, 3H), 1.31 (dd,J=6.0, 3.3 Hz, 3H).

[0372] LRMS (ESI)m / z([M+H] + ) calcd for C 55 H 53 C l2 N7O 11 : 1058.3, found 1058.3

[0373]

[0374] 실시예 1: CRBN 리간드를 사용한 MDM2 표적 PROTAC 개발

[0375] The intracellular MDM2 protein degradation ability was evaluated by treating 14 types of MDM2-PROTAC (10 μM) synthesized in human dental pulp stem cell lines (hDPSC) for 1 hour and performing Western blot using SDS-PAGE gel.

[0376] As shown in Fig. 1a and Fig. 1b, the degradation of MDM2 was confirmed. As shown in Fig. 2, based on the first-selected compounds, two compounds (compound 6b and compound 16b) and treatment concentrations that effectively degrade MDM2 and activate p53 were selected.

[0377] Example 2: Induction of osteogenic differentiation

[0378] Human dental pulp stem cell lines (hDPSC) were treated with secondary selected compounds, compound 6b, compound 16b, and compounds 17 to 21, at a concentration of 1 μM for 2 weeks, fixed with 4% PFA, and then the degree of differentiation into osteoblasts was evaluated through Alizarin Red S staining. Human dental pulp stem cell lines (hDPSC) were treated with secondary selected compounds, compound 6b, compound 16b, and compounds 17 to 21, at a concentration of 1 μM for 2 weeks, and then quantitative PCR was performed to confirm the genetic changes in osteogenic differentiation markers BMP2 and RUNX2.

[0379] Figures 3a and 3b show the results of confirming the biomineralization effect (A) and the expression of osteogenic differentiation marker genes for the secondary selected compounds through Alizarin Red S staining.

[0380] Figure 3c shows the results of confirming the biomineralization effect through Alizarin Red S staining for compounds 17 to 21.

[0381]

[0382] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

[0383]

[0384] The novel nutlin-based compound according to the present invention effectively promotes differentiation of mesenchymal stromal cells by inducing degradation of MDM2, a negative regulator of p53, and thus has an excellent effect in inducing osteogenic differentiation of stem cells.

[0385]

[0386] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: wherein X is C, O or N, and n is an integer from 1 to 5, The above Z is an integer from 1 to 10, The above m is an integer between 1 and 10, The above YW is C≡C, or both Y and W are C, or the above Y is C and W is O, The above v is an integer of any one of 1 to 4, The above A is C or N A compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein l is any integer from 1 to 8.

2. .

3. .

4. .

5. .

6. .

7. In paragraph 1, a compound comprising at least one selected from the group consisting of: a stereoisomer thereof or a pharmaceutically acceptable salt thereof: 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5 dihydro-1H-imidazole-1-carbonyl) -2-oxopiperazin-1-yl)-N-(5-((2-(2,6dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl) acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(8-((2-(2,6-dioxo-opiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl) acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(11-((2-(2,6-dioxop-erydin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy) undecyl) acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)) oxy) ethoxy) ethyl) acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(2-(2-((2-(2,6-dioxo-opiperidin-3-yl))-1,3-dioxoisoindoline-) 4-yl)oxy)ethoxy)ethoxy)ethoyl)acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl))-1,3-dioxo) isoindolin-4-yl)oxy))ethoxy)ethoxy)-ethoxy)ethyl)-acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl))oxy)acetamide)ethyl)-acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(5-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) ) oxy) acetamide) pentyl-l) acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(8-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl))oxy)acetamide)octyl)-acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(6-(2-(2,6-dioxopipe-lysin-3-yl)-1,3-dioxoisoindolin-4-yl)hexa-5-yn-1-yl) acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)non-8-yn-1-yl) acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)-2-oxopiperazin-1-yl)-N-(12-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) dodeca-11-yn-1-yl) acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)phenyl) but-3-yn-1-yl)acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)phenyl) butyl)acetamide; 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)nonyl)acetamide; and 2-(4-(cis-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)- 2-oxopiperazin-1-yl)-N-(2-((4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)benzyl )oxy)ethyl)acetamide.

8. A composition for inducing osteogenic differentiation of stem cells, comprising a compound according to any one of claims 1 to 7, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition characterized in that it is formulated in any one dosage form selected from the group consisting of injections, oral administration preparations, patches, liquids, capsules, granules, tablets, powders, sprays, ointments, gels, mucosal administration preparations, and suppositories in the 8th paragraph.

10. A pharmaceutical composition according to claim 8, characterized in that it further comprises a pharmaceutically acceptable carrier.

11. A pharmaceutical composition according to claim 8, wherein the daily dosage of the compound, its stereoisomer, or its pharmaceutically acceptable salt is 1 μg / kg to 100 mg / kg, and is administered once a day or 2-3 times a week.

Citation Information

Patent Citations

  • Imide-based modulators of proteolysis and associated methods of use

    KR1020170002446A

  • MDM2 protein degraders

    KR1020180132125A

  • Robot apparatus and method for following moving object based on drivable area

    KR102796329B1

  • Bifunctional nutlin-lenalidomide derivatives ((4,5-dihydro-1h-imidazole-1-carbonyl)piperazin-1-YL-[linker]-1-oxoisoindolin-2-YL)piperidine-2,6-dione derivatives) as MDM2 degraders and MDM2-p53 inhibitors for use in cancer therapy

    WO2020232115A1